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Welcome to the 6th Biennial Heart Valve Biology and Tissue 
Engineering Meeting, which promises to be a stimulating and 
informative meeting with a truly international faculty and audience.   
The field of heart valve biology and tissue engineering a heart valve 
continue to expand. The presentations at this meeting reflect the 
advances made in both areas due to the multi-disciplinary approach 
taken by many laboratories.  
This meeting provides a forum that fosters an environment in which 
these advances can be reported and discussed. There are also a 
number of keynote lectures at the start of each session, providing a 
state-of-the-art perspective for each session. Lastly, Wednesday 
evening entails a fully moderated poster session and a prize for the 
best poster. 
On Thursday evening you are invited to join us on the boat cruise 
along the river Thames, through the heart of London, where you will 
be able to enjoy excellent views of many of the London landmarks 
as well as some good food and excellent company.  
We hope you enjoy the meeting and the wonderful facilities offered 
by the Royal Society in this historic and inspiring environment!   
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The Royal Society, is a learned society for science, and is possibly the oldest such 
society still in existence. Founded in November 1660, it was granted a Royal Charter 
by King Charles II as the "Royal Society of London". The Society today acts as a 
scientific advisor to the British government, receiving a parliamentary grant-in-aid. 
The Society acts as the UK's Academy of Sciences, and funds research fellowships 
and scientific start-up companies. 
The Royal Society started from groups of physicians and natural philosophers, 
meeting at variety of locations, including Gresham College in London. They were 
influenced by the "new science", as promoted by Francis Bacon in his New Atlantis, 
from approximately 1645 onwards. A group known as The Philosophical Society of 
Oxford was run under a set of rules still retained by the Bodleian Library.  
After the English Restoration, there were regular meetings at Gresham College. It is 
widely held that these groups were the inspiration for the foundation of the Royal 
Society. 
The Society has a variety of functions and activities. It supports modern science; it 
finances approximately 700 research fellowships for both early and late career 
scientists, along with innovation, mobility and research capacity grants. Its Awards, 
prize lectures, and medals all come with prize money intended to finance research, 
and it provides subsidised communications and media skills courses for research 
scientists. Through its Science Policy Centre, the Society acts as an advisor to the 
European Commission and the United Nations on matters of science. It publishes 
several reports a year, and serves as the Academy of Sciences of the United 
Kingdom. Since the middle of the 18th century, government problems involving 
science were irregularly referred to the Society, by 1800 it was performed  
accordingly. 
The premises in which we are now in are a Grade I listed building and the current 
headquarters of the Royal Society. The first Carlton House was named after Baron 
Carleton, and was sold to Lord Chesterfield in 1732, who held it on trust for 
Frederick, Prince of Wales. Frederick held his court there until his death in 1751, 
after which it was occupied by his widow until her death in 1772. In 1783, the then-
Prince of Wales, George, bought the house, instructing his architect Henry Holland 
to completely remodel it. When George became King, he authorised the demolition 
of Carlton House, with the request that the replacement be a residential area. John 
Nash eventually completed a design that saw Carlton House turned into two blocks 
of houses, with a space in between them. The building is still owned by the Crown 
Estates and leased by the Society; it underwent a major renovation from 2001 to 
2004 at the cost of £9.8 million, and was re-opened by the Prince of Wales on 7th 
July 2004. 
The Society is governed by its Council, which is chaired by the Society's President, 
according to a set of Statutes and Standing Orders. The members of Council and the 
President are elected from, and by, its Fellows, the basic members of the Society, 
who are themselves elected by existing Fellows. There are currently about 1,450 
Fellows, allowed to use the post nominal title FRS (Fellow of the Royal Society), with 
up to 52 new Fellows appointed each year. There are also Royal Fellows, Honorary 






The conference dinner will be aboard the Pride on London riverboat. The boat will 
depart from Westminster Pier (see map) within a 10 minute walk from the Royal 
Society. The boat will depart at 19.45 and will return to Westminster at approximately 
23.45. There will be a buffet style BBQ on the boat along with wine, beer and soft 
drinks. The boat is covered, with an upper viewing deck. 













































































































































































































































































































































































































































































































































































































































































































































































































































Endothelial to mesenchymal transformation (EndMT) is a valve 
morphogenic mechanism associated with aortic valve regeneration and 
disease initiation. The aortic valve fibrosa is the initial site of 
inflammatory and calcific degeneration, and EndMT occurs on the valve 
fibrosa local to calcified nodules. In healthy valves, the fibrosa matrix is 
primarily composed of circumferentially-aligned, collagen fibers. Valve 
disease is characterized by the deposition of chondroitin sulfate and 
dermatan sulfate-rich proteoglycans into the sub-endothelial fibrosa 
layer, and the presence of the glycosaminoglycan (GAG) hyaluronan 
near calcified nodules. The goal of our work is to identify if and how this 
altered extracellular matrix (ECM) composition promotes EndMT and 
eventual calcification. In this study we examined aortic valve endothelial 
cell response to ECM changes using in vitro cell cultures and hybrid 
continuum-stochastic modeling. Our in vitro results show that the 
addition of GAGs (chondroitin sulfate, dermatan sulfate, and hyaluronan) 
to a 3D collagen I-based matrix strongly induces EndMT.  Our 
computational model captures EndMT and cell migration within the local 
ECM environment. The composition, structure, and mechanical behavior 
of the ECM are expressed in the adhesion stresses during stochastic 
EndMT and resistance to biased cell migration. The model has been 
developed to contain measurable quantities validated by our in vitro 
experimental data and to predict which cell-ECM interactions are critical 
to mesenchymal transformation and cell migration. Determining the 
matrix cues that induce and promote EndMT will advance tissue 
regeneration strategies, tissue engineering approaches, and 



















Embryonic valves rapidly evolve from disorganized globular “cushions” 
to highly organized thin fibrous leaflets.  These multi-scale interactions 
occur within a demanding hemodynamic environment and are essential 
to maintain unidirectional flow. The mechanisms by which mechanical 
forces direct cellular response to coordinate this cycle of morphogenesis 
and function are not known. In this study, we determined how 
mechanosensitive small GTPases RhoA and Rac1 coordinate 
atrioventricular valve (AV) differentiation and morphogenesis.  RhoA 
activity is elevated during early cushion formation, but decreases 
considerably over development.  In contrast, active Rac1 increases as 
cushions mature into valves. Using gain and loss of function assays, we 
determined that the RhoA-SRF pathway was essential for a 
myofibroblastic contractile phenotype in early cushion formation, but was 
surprisingly insufficient to drive matrix condensation during valve 
maturation.  Instead, sustained cyclic stretch was a potent inhibitor of 
myofibroblastic activation by decreasing RhoA-GTP levels, and 
promoted a Rac1 signaling “switch” via nuclear membrane localization of 
FilGAP.  The downstream Rac1-p38 pathway was necessary and 
sufficient to cause directed matrix condensation through cell polarization, 
leading to enhanced stress fiber alignment and adhesion necessary for 
valvular remodeling.  Finally, we used partial atrial ligation experiments 
to show that altered cyclic mechanical loading in vivo augmented or 
restricted cushion growth directly through potentiation of RhoA and Rac1 
activity. Together, these results demonstrate that mechanical signaling is 
essential to coordinate a transition from RhoA to Rac1 based signaling, 












Delineating the normal postnatal development of the pulmonary artery 
(PA) and valve can inform our understanding of congenital 
abnormalities. Utilizing the extensive experimental structural and 
mechanical measurements from our previous study, we developed a 
structural constitutive model for the growing PA at the juvenile and adult 
stages. Our key findings were that while there are regional variations 
with age, the major effects of the age related changes were exhibited in 
the medial aspect of the PA wall.  Specifically, we observed that 
structurally, the elastin and collagen fibers' in-plane splay underwent 
opposite changes, and a trend towards more rapid collagen fiber 
recruitment with respect to strain. The most profound changes were 
observed with the fiber moduli, with the elastin modulus increasing by 
~50% and the collagen modulus reducing to only ~25% of the juvenile 
value. As observed in our geometric studies the focal changes observed 
in the medial region are likely due to the impingement of relatively stiff 
ascending aorta on the growing PA. Clearly, during the postnatal 
somatic growth, local stresses can substantially modulate the 
development of regional tissue microstructure and mechanical behaviors 
in the PA. Finally, we underscore that in our previous studies suggest an 
increase in effective PA wall stress with postnatal maturation. This 
observation is contrary to the accepted theory of maintenance of 
homeostatic stress levels in the regulation of vascular function, and 
suggests alternative mechanisms regulate postnatal somatic growth. 
ACKNOWLEDGMENTS  













Valve interstitial cells comprise the main fibroblastic component of valve 
leaflets however in culture it is accepted that they differentiate into a 
myofibroblastic phenotype. A fibroblast culture media (FIB) formulation 
was assessed for its ability to maintain the fibroblastic phenotype. 
Normal human VICs were cultured in standard DMEM and in FIB 
consisting of FGF2 (10ng/ml), insulin (50ng/ml) and 2% FCS for at least 
one week. VICs in DMEM exhibited large, spread cells whereas VICs in 
FIB were smaller, elongated and spindly. Aspect ratio and size were 
both significantly higher in DMEM (p<0.01). The level of expression of α-
SMA was significantly reduced in DMEM (p<0.01). There was a 
significant decrease in the proliferative potential of VICs in FIB after 1 
(p<0.05) and 2 (p<0.01) weeks in culture. Contraction of collagen gels 
was significantly reduced in FIB from 4 hours post dislodgment (p<0.05). 
Focal adhesions were assessed in relation to this contraction and VICs 
were found to have significantly fewer supermature (p<0.001) and 
smaller focal adhesion (p<0.01) in FIB. VICs in FIB demonstrated a 
slower migratory ability after wounding at 72 hours (p<0.01). Treatment 
of human VICs with this FIB formulation has the ability to dedifferentiate 
the VICs back to a fibroblastic phenotype with phenotypic and functional 
characteristics ascribed to quiescent VICs. The use of quiescent VICs in 
the study of normal valve biology, pathology and in the field of tissue 















Aortic valve disease may be life threatening and is highly prevalent 
conditions in Western countries whose impact is continuously increasing 
in the aging population. Among the aortic valve disease, bicuspid aortic 
valve (BAV) occurs when the aortic valve has two cusps, rather than 
three, and represents the most common form of congenital cardiac 
malformation, affecting 1-2% of the population. Despite the clinical 
significance of this pathology, its etiology is poorly understood. To date, 
only few genes (as NOTCH1, HOXA1 or TGFBR2) have been 
associated with BAV. Our recent work showed that the transcription 
factor Krox20 is expressed in the mesenchymal cells of the aortic valves 
of embryo and adult mice. Krox20 mutant embryos develop abnormal 
aortic valves with hypercellularization of interstitial cells and 
disorganization of the extracellular matrix (ECM). Our data revealed that 
aortic valve defect is caused by increased contribution of cardiac neural 
crest-derived cells and direct downregulation of fibrillar collagen Col1a1 
and Col3a2 genes. Here, we report that 25% of Krox20 mice have BAV. 
This defect is essentially due to a failure of normal development of the 
embryonic cushions in the outflow tract resulting in a fused right- and 
non-coronary cusp. Our analysis shows that Krox20 regulated 
transcriptional levels of eNos (endothelial nitric oxide synthase), which is 
required for endothelial differentiation and vascular remodeling. We are 
currently analyzing the genetic interaction between Krox20 and eNos. 

















Marfan syndrome is caused by mutations in the gene that encodes 
fibrillin-1. Mitral valve prolapse is a cardiovascular complication in 
Marfan patients. This study examined the mitral valve of normal controls, 
untreated Marfan mice (using the murine model of Marfan syndrome, 
C1039G) and Marfan mice treated with either: Pravastatin (100mg/kg); 
Losartan (60mg/kg) or Doxycycline (24mg/kg). Valves were analysed 
both ultrastructurally and stereologically. 
The C1039G murine model of Marfan Syndrome exhibits ultrastructural 
changes in the mitral valve compared to control animals. These include 
aberrant collagen orientation and phenotypic change to Valvar Interstitial 
Cells (VIC). Pharmacological treatment of the Marfan mouse is seen to 
change the microanatomy of the mitral valve; using transmission 
electron microscopy and a variety of stereological techniques these 
changes are demonstrable and quantifiable. Of the three 
pharmacological treatments used, pravastatin is the only one to 
decrease mitral cusp thickness whilst both Doxycycline and Losartan 
increase valve thickness in µm (40.96 +/-13.26) above the level of 
Marfan Syndrome - itself thicker than the control. This may have 
implications in valve stiffness and compliance during the cardiac cycle. 
Marfan Syndrome and each treatment group exhibited an increase in the 
absolute volume of VIC per µm3 (221.29 +/-59.49), VIC nucleus (101.82 
+/-25.41)and VIC rER (27.24 +/-11.51) compared to control. VIC and 
VIC rER was greatest in the pravastatin treated group. This may suggest 
that pravastatin treatment of Marfan Syndrome mice may have a 
beneficial effect on protein production by VICs in the mitral valve, 












Calcific aortic valve disease (CAVD) is characterized by calcific nodule 
formation, stenosis of the valve, and induction of an osteogenic gene 
program. Klotho-deficient mice were used to study the molecular 
mechanisms and cellular origins of CAVD as they develop robust aortic 
valve (AoV) calcification. Through microarray analysis of AoV tissues 
from klotho-deficient and wild type mice, increased expression of the 
gene encoding cyclooxygenase 2 (COX2) was found. Aside from a role 
in inflammation, COX2 activity contributes to bone differentiation and 
homeostasis.  Thus, we hypothesize that COX2 has a critical role in AoV 
calcification. In klotho-deficient mice, COX2 expression is increased 
throughout regions of AoV calcification in the valve interstitial cells 
(VICs). Similarly, COX2 expression is increased in human CAVD. To 
determine if the developmental origin of VICs confers a unique potential 
to calcify, the contribution of endothelial versus neural-crest derived 
VICs to the calcified area was assessed in klotho-deficient mice. COX2-
expressing VICs in calcified regions were primarily of neural crest origin 
and rarely of endothelial origin, suggesting that neural crest derived 
VICs activate COX2 gene expression and have the capacity to calcify. 
Treatment of cultured porcine VICs with osteogenic media induced bone 
marker gene expression, which was blocked by inhibition of COX2 
activity. Furthermore, genetic loss of function or pharmacological 
inhibition of COX2 activity reduced AoV calcification and blocked 
osteogenic gene induction in klotho-deficient mice. Thus, COX2 
expression is activated in calcifying VICs of neural crest developmental 



















Enzymes of extracellular nucleotide metabolism participate in regulatory 
functions, such as immunomodulation, thromboregulation, bone 
remodeling or cell proliferation by controlling extrcellular nucleotide 
metabolite concentrations. In valves, disturbances of these processes 
may lead to calcification. This study aimed to investigate the changes in 
extracellular nucleotide metabolism in pathology of human aortic valves. 
Stenotic aortic valves were obtained from patients after aortic valve 
replacement (n=100) and non-stenotic valves were obtained after heart 
transplantation or Bentall procedure (n=20). Valves were analyzed for 
ecto-nucleoside triphosphate diphosphohydrolase (eNTPD), ecto-5’-
nucleotidase (e5NT) and ecto-adenosine deaminase (eADA) activities 
by exposing specific area of fibrosa or ventricularis side to medium with 
nucleotide substrates and tracing conversions by high perfomance liquid 
chromatography. These measurements were correlated with clinical 
data. 
On the fibrosa of stenotic aortic valve, activities of eNTPD, e5NT and 
eADA were 1.80±0.09, 1.11±0.06, 0.95±0.07 nmol/min/cm2 respectively. 
Whereas, in the non-stenotic valves these activities were higher: 
2.60±0.32 (eNTPD) and 2.11±0.21 (e5NT) or lower: 0.55±0.09 
nmol/min/cm2 (eADA). No differences between stenotic and non-stenotic 
valves were observed on the ventricular side. Negative correlations were 
found between: eNTPD and e5NT activities and plasma low density 
lipoproteins as well as between eADA activity and ejection fraction. 
Positive correlation was demonstrated beetween eADA activity and left 
ventricular end-systolic diameter. 
These results demonstrate that extracellular nucleotide breakdown in the 
valve is adversely modified in aortic stenosis. Diminished activities of 
eNTPD and  e5NT with increase in eADA activity may affect extracellular 
















Certain pathological processes give rise to ectopic soft tissue 
calcification. A better understanding of the structures and nano-scale 
architecture of ectopic calcification in tissues such as aortae affected by 
arteriosclerosis and other calcific diseases can lend insight into the 
biomineralisation process of the different diseases. Aortae, aortic valve, 
and coronary artery samples from patients and healthy human donors 
were analysed using Raman spectroscopy and scanning electron 
microscopy with energy-dispersive X-ray spectroscopy (SEM-EDS). A 
previous study in our group identified spherical calcium phosphate 
deposits within aortic tissues of diseased and even healthy donors. 
These spherical deposits were a highly crystalline form of calcium 
phosphate1, 2. In this study, further characterisation with Raman 
mapping of the aorta wall tissue supports these results, based on 
intensity heat maps of the 960 cm-1 calcium phosphate and the 1080 
cm-1 phosphate bands; indicating discreet regions of calcium phosphate 
deposits within the tunica media of the aortic wall tissue. Furthermore, 
the mineral composition of the calcified spheres was determined to be 
magnesium-substituted hydroxyapatite, as found by Raman, EDS, and 
ICP, in stark contrast to calcification of atherosclerotic plaques and bone 
mineral, which are poorly crystalline apatite. Interestingly, this is true for 
calcified spheres of the tunica media in both healthy and diseased 
tissue, suggesting the same origin. This study indicates that the 
calcification in vascular tissues is different from that of bone. The 
characterisation and study of these tissues can thus contribute to a 


















Calcific aortic valve disease (CAVD) shares several features with 
osteogenesis. This pathological process is similar to normal 
development of bone, phenotypically and transcriptionally. Because the 
retinoblastoma protein (Rb) pathway is critical to bone development, we 
hypothesized that the Rb pathway also regulates development and 
progression of CAVD. To test this hypothesis we cultured porcine aortic 
valve interstitial cells (pAVICs) infected with lenti-viruses expressing 
shRNA constructs targeting porcine Rb mRNA. Knockdown of the Rb 
transcript was confirmed by qRT-PCR (80% and 69% reduced 
expression by shRb1 and shRb3, respectively, p<0.005)) and we 
consistently observed reduced Rb protein by Western blot compared to 
a scrambled shRNA control. AVICs lacking Rb had similar ki-67 positivity 
compared to control cells (21-36%, p=NS), suggesting that cell-cycle 
regulation is not impaired in pAVICs  with Rb knockdown. Calcification 
was induced by culturing the pAVICs in medium treated with ascorbic 
acid, B- glycerophosphate, and dexamethasone. After three weeks, 
expression of bone-specific genes (Runx2, alkaline phosphatase, 
osteocalcin and osteonectin) was increased compared to pAVICs 
cultured in normal medium, as determined by qRT-PCR analysis. 
Calcification, detected by alizarin red S staining, was significantly higher 
in cells treated with calcification medium (p<0.05).  We observed 
modestly increased calcification of pAVICs transformed with the shRb3 
construct compared to scrambled control. The role of pRb in pAVIC 
calcification is currently under investigation both in vitro and in vivo by 
cre-mediated knockout. These studies will determine the potential role 












Accelerated progression of calcific aortic valve disease (CAVD) is 
frequently observed in patients with end stage renal disease (ESRD) 
however the cellular mechanisms responsible remain unclear. Elevated 
serum calcium (Ca) and phosphate (Pi) levels in ESRD patients 
enhance vascular smooth muscle cell calcification and the subsequent 
release of matrix vesicles (MV), which are specialised structures that 
initiate mineral nucleation. In the present study, we determined whether 
valve interstitial cells (VICs) contribute to aortic valve calcification 
through the release of MVs. 
Rat VICs were cultured with control medium or calcifying medium 
containing 2.7 mM Ca and 2.5mM Pi (Ca x Pi) for 3 days. A significant 
increase in calcium deposition was observed (10.8 fold, P<0.001) by 
quantitative calcium assay and alizarin red staining. In addition, elevated 
levels of Ca x Pi significantly increased the mRNA expression of 
calcification regulators PiT-1 (1.6 fold, P<0.01), Enpp1 (2.9 fold, P<0.01) 
and Phospho1 (2.6 fold, P<0.001). However, the expression of the 
osteogenic markers Runx2, Ocn, and Msx2 were unaltered. MVs 
released by rat VICs were harvested by ultracentrifugation. Western 
blotting revealed that MVs released through Ca x Pi stimulation showed 
increased expression of the MV markers Annexin 2 and Annexin 6. 
These studies are the first to establish the in vitro calcification of rat VICs 
as a model of CAVD. Our data has demonstrated that calcifying VICs 
release MVs, suggesting a potential novel mechanism underpinning the 













The role of eNOS uncoupling in aortic valve disease progression is 
unknown, despite its known role in vascular pathology. Here we show 
that inflammation drives increased valve oxidative stress via eNOS 
uncoupling, leading to endothelial dysfunction and calcification. Inhibition 
of eNOS uncoupling and its effects with tetrahydrobiopterin or 
superoxide dismutase can mitigate valve degeneration by blocking the 
downstream effects of eNOS uncoupling. 
Calcified human aortic valves expressed side-specific elevation of 
superoxide levels in the endothelium, co-localized with high VCAM-1 
expression, linking oxidative stress, inflammation, and valve 
degeneration. TNFα treatment increased superoxide and decreased 
eNOS and VE-cadherin acutely over 48 hours in aortic valve endothelial 
cells (VEC) and chronically over 21 days in ex vivo AV leaflets.  Co-
treatment of VEC with tetrahydrobiopterin (BH4) but not apocynin 
mitigated TNFα-driven VEC oxidative stress, indicating eNOS 
uncoupling as the primary mechanism of increased valve endothelial 
oxidative stress. Co-treatment of VEC or ex vivo AV leaflets with 
TNFα+BH4 or TNFα+superoxide dismutase (SOD) rescued endothelial 
function and mitigated inflammatory responses. In ex vivo AV leaflets, 
TNFα additionally caused extracellular matrix disorganization, 
myofibroblastic activation, and calcium and mineral deposition, which 
were ameliorated by co-treatment with TNFα+BH4 or TNFα+SOD. 
These results present endothelial inflammatory oxidative stress as a new 
mechanism that connects early valve pathology with later stages of 
degeneration. Targeting these mechanisms via tailored antioxidant 











Male sex is a significant risk factor for developing calcific aortic valve 
disease (CAVD), but this phenomenon has not previously been 
investigated on the cellular scale. Cellular-scale sex-related differences 
have been noted in other cardiovascular conditions, leading us to 
investigate whether male and female valvular interstitial cells (VICs) 
exhibit differential behavior in the context of CAVD. VIC cultures have 
not previously been separated by sex, and in vitro evaluation revealed 
intrinsically higher apoptosis, proliferation, and αSMA expression in male 
porcine VICs compared to female VICs; all of these markers are 
associated with CAVD pathobiology. Additionally, male VICs were 
significantly more sensitive to treatment with TGF-beta1, an 
inflammatory cytokine that plays a key role in CAVD progression. For 
instance, in male VICs, αSMA was significantly increased by TGF-beta1 
and decreased by a neutralizing antibody to TGF-beta1, while female 
VICs were unresponsive to both treatments; endogenous TGF-beta1 
production was similar across sexes. Expression of alkaline 
phosphatase was significantly decreased upon TGF-beta1 treatment of 
male VICs, while female VICs were unresponsive. Male VICs expressed 
higher levels of TGF-beta receptor 2, which may be one mechanism by 
which males exhibit increased sensitivity to this stimulus. Moreover, 
equivalent levels of phosphorylated Smad2 but increased p38 MAPK 
phosphorylation in male VIC cultures indicate involvement of the non-
canonical TGF-beta1 signaling pathway in these sex-related differences. 
The finding that male and female VICs exhibit significant cellular-scale 
differences, particularly in their responsiveness to pro-disease stimuli, 
has the potential to substantially impact our characterization of CAVD 














Familial hypercholesterolemia (FH) is a prevalent hereditary disease 
associated with coronary artery disease and increased risk of calcific 
aortic valve disease (CAVD). The Rapacz familial hypercholesterolemic 
(RFH) swine is a well-established model of human FH and 
atherosclerosis in general, but has not been studied in the context of 
CAVD. We hypothesized that these unique animals may provide insight 
into CAVD pathobiology and its relationship to atherosclerosis. Coronary 
arteries and aortic valves from wild-type and RFH swine (0.25, 1, 2, and 
3 year-old) were characterized across multiple scales and found to 
possess complex atherosclerotic lesions and hallmarks of early-stage 
human CAVD, respectively. Adult RFH swine exhibited significant leaflet 
thickening, increased lipid oxidation, macrophage infiltration, and 
extensive extracellular matrix remodeling, including proteoglycan 
enrichment, collagen disorganization, and elastin fragmentation. 
Intracardiac echocardiography showed leaflet thickening in adult RFH 
aortic valves, and valve function ranged from unimpaired to mildly 
sclerotic. Microarray analysis of adult and juvenile RFH valves revealed 
significant upregulation of inflammation-related genes and several 
commonalities with atherosclerosis; pathway analysis also showed 
substantial overlap of the RFH model with previous microarray 
comparisons of healthy vs. diseased human valves. Overall, adult RFH 
swine exhibited several hallmarks of early human CAVD that have not 
previously been demonstrated in other animal models, and may help to 
elucidate CAVD etiology in both FH and non-FH individuals. The 
development of advanced atherosclerotic lesions but only early-stage 
CAVD in RFH swine also support the hypothesis of an initial shared 
disease process, with additional stimulation or co-morbidities necessary 
















C-type natriuretic peptide (CNP), which signals through the particulate 
guanylate cyclase receptor NPR2, is elevated in disease-protected 
regions of the aortic valve and reduced in stenotic valves. In vitro, CNP 
inhibits valvular cell myofibro/osteoblastogenesis, yet its functional 
impact in vivo is unknown. 
Male Npr2+/- mice and WT littermates were aged for 4 or 8 months (n = 
9-15/group). Valve/cardiac function was assessed by echocardiography, 
and valve matrix composition/morphology by Movat's. 
4-month Npr2+/- mice developed deficits in aortic valve function, with 
elevated transvalvular velocity (normalized to ejection fraction; V/EF) 
(+30.7% vs. WTs, p < 0.01). V/EF was further increased in 8-month 
Npr2+/- mice vs. WTs (+44.4%, p < 0.001). This was accompanied by 
impaired systolic function in 8-month Npr2+/- mice: EF, fractional 
shortening, and left ventricular outflow tract velocity were reduced by 
22.0%, 26.9%, and 18.5%, respectively, vs. all others (p < 0.001). Npr2+/- 
leaflets were thickened, rich in proteoglycans, and developed 
collagenous remodeling of the attachment region. 9.5% of Npr2+/- mice 
have congenital bicuspid aortic valves (BAVs) (none in WTs), with the 
worst valve function (V/EF increased by 70.0% vs. tricuspid Npr2+/- mice, 
p < 0.01), flow disturbances, most severe leaflet proteoglycan 
accumulation, fibrosis, and evidence of calcification. 
Thus, impaired CNP signaling produces valvular/LV dysfunction and 
increases BAV incidence. These findings reveal a functional role for 
CNP in the aortic valve, suggest therapeutic strategies, and establish a 
novel BAV mouse model. They also broadly implicate guanylate cyclase 
family signaling in valvular development, complementing evidence from 



















Myxomatous mitral valve disease (MMVD) is a pathological condition 
resulting in mitral regurgitation (MR) and is only treated surgically at 
present. Increasing evidence suggests that mitral valve interstitial cells 
(MVICs) play a critical role in the pathological remodeling of the MV. 
Serotonin (5HT) is a neurotransmitter, and if present at increased levels 
can cause a valvulopathy. This suggests that 5HT-receptor (5HTR) 
signaling plays a physiologic role, and that increased 5HTR activity 
could mediate the pathophysiology of valve disease. Here we test the 
hypothesis that 5HTR antagonism can alter the pathological prolapse of 
the MV in vitro and ex vivo. 
Using microarray (N=4/group) and histological analysis on human 
specimens we show upregulation of serotonin receptors (5HR) 2A and 
2B on MMVD patients vs. controls (+12.5 and +28.4 folds, respectively; 
p-value <0.001) Immunological analysis on surgically explanted tissues 
show pathological remodeling of the MV leaflets (increased thickness 
and ECM accumulation) with concomitant activation of 5HT signaling 
and MVIC activation (5HTR2A+, 5HTR2B+, OPN+, SMA+, RUNX2+). In 
vitro assay on human isolated MVICs (6 days), as well as ex-vivo 
biomechanical testing of human MV (6 days at 15% and 1 Hz using a 
uniaxial tensile bioreactor), were performed with results showing that 
VICs activation is associated with 5HTR activation and that 100 mm 
Ketanserin (5HTR1A antagonist) reverts these effects. 
It is concluded that the pathological remodeling of the MV in the setting 
of myxomatous prolapse is associated with 5HT signaling. These results 
could have important implications for testing therapeutic candidates 











Mitral leaflet remodeling, i.e. its expansion and fibrosis has been recently 
demonstrated in ischemic heart disease(IHD), and the leaflet remodeling 
capacity has been attributed to chronic leaflet tethering. In our study, we 
compared the extent of leaflet remodeling in human patients with IHD , 
and compared against patients with aortic stenosis(AS) with similar-
sized ventricles and valve tenting. Cardiac gated phase contrast MRI 
was performed in 76 humans with ischemic heart disease with mitral 
regurgitation (MR severities: mild-45; severe-31) and compared with 10 
humans with severe aortic stenosis with equivalent dilated ventricles. 
Left ventricular volume (LVV), mitral regurgitant volume (MRV), tenting 
area (TA) were measured in either groups, and leaflet remodeling was 
quantified as diastolic anterior and posterior leaflet lengths (ALL,PLL) 
normalized by the body surface area. LVV did not differ between 
patients with IHD and AS. In IHD patients, ALL and PLL increased 
significantly from mild MR to severe MR. A 25% increase in ALL from 
12.5 ± 3.3 mm/m2 in mild MR to 15.6 ± 3.4 mm/m2 to severe MR 
(p=0.004) was measured, while a 42% increase in PLL was measured 
(p<0.001). Both ALL and PLL has a significant correlation with MRV 
(ALL: r=0.37, P=0.001; PLL: r=0.42, P=0.0002), and TA. AS patients 
with identical LV size, but without an infarction or regurgitation had 
shorter leaflets as compared to MR patients. Leaflet remodeling is an 
active process in IHD patients, and seemed to rely on the presence of 
















Mutations in the gene encoding Filamin-A, a cytoskeletal protein, were 
identified in patients with familial mitral valve prolapse(MVP). In this 
study, we sought to investigate the impact of these mutations on 
cultured cells in comparison with wild type Filamin-A, to delineate the 
mechanisms underlying MVP. 
Four immortal cell lines were established - Filamin-A KO, Filamin-A WT, 
G288R mutated Filamin-A, and P637Q mutated Filamin-A. Cells were 
cultured on plastic petri-dishes for a week, and at confluence the cells 
were imaged under a microscope, then their 3D morphology and 
mechanical stiffness measured with scanning ion conductance 
microscopy, and then the cells were assayed for integrins and counted 
using flow cytometry. 
Filamin-A KO cells developed blebs on the surface, were flat and did not 
sufficiently attach to the cell culture substrate, while WT cells 
demonstrated excellent attachment and formed extensive lamellapodi 
and filipodia. Both G288R and P637Q mutated cells had reduced 
extensions, with a cell structure that is small in circumference but large 
in height. α1, α2, α3, α5, β1, β3, β4, α5β3, α2β1 integrin expression was 
drastically reduced in both G288R and P637Q mutations, compared to 
WT. A 24 hour substrate attachment assay demonstrated 30% 
attachment of G288R cells were attached and viable, 50% of the P637Q 
cells were attached and viable, and 98% of WT cells were attached and 
viable, with similar results seen in gel contraction studies. 
Filamin-A mutations associated with mitral valve prolapse seem to alter 
fundamental cellular mechanisms essential for cell attachment to matrix, 












The extracellular matrix (ECM) determines multiple aspects of tissue 
biology. Greater understanding of ECM as an extracellular source of 
cytokines mediating paracrine regulation of tissue function will better 
inform tissue engineering strategies for replicating ECM biology. During 
response to injury, extracellular latent TGF-β is activated and released to 
mediate remodeling in many tissues. To understand how mechanical 
forces regulate leaflet homeostasis, we study responses of native heart 
valves to chronic changes in flow. Using an ex vivo model in which 
multiple rat pulmonary valves are cultured 7-days together under flow 
(cycling) or static (non-cycling) conditions, we find that leaflets remodel 
in response to a chronic change in flow, accompanied by marked 
changes in the expression of multiple genes. Intriguingly however, we 
observed that TGF-β gene expression was unchanged between flow and 
static conditions. To investigate whether activation of latent TGF-
β modifies gene expression changes induced by altered mechanical 
force in leaflets, valves were cultured in the presence of the TGF-β-
Receptor-1/Alk-5 kinase inhibitor LY2157299. We found that the 
expression of genes highly regulated (4 to16-fold) in response to 
chronically altered flow was markedly reduced by LY2157299 treatment: 
63±15% (mean decrease±SD; n=8) from the non-drug fold-change in 
gene expression. The effects of TGF-β receptor signaling inhibition on 
force-regulated gene expression demonstrate the presence of leaflet 
tissue-level paracrine TGF-β signaling. Amplification of mechano-
sensitive gene expression by extracellular TGF-β reveals a robust and 
complex signaling network for the regulation of leaflet homeostasis, and 















Aortic Valve (AV) experiences dynamic mechanical environment, which 
when altered can lead to inflammation and calcification, preferentially on 
fibrosa side. Using porcine AV, our ex vivo studies showed that altered-
shear conditions induced inflammatory markers (ICAM-1, VCAM-1, 
BMP-4) preferentially on fibrosa. This shear- and side-dependent AV 
pathophysiology is attributable, in part, to the altered gene expression. 
MicroRNAs (miRs) are short noncoding RNAs that post-transcriptionally 
regulate gene expression and have been shown to regulate cardiac 
development and disease. Previously, our microarray studies on human 
AV endothelial cells showed that miRs-181a, 181b, 199a, and 214 
responded differently to altered-shear conditions.  It is hypothesized that 
these miRs are shear- and side-dependent and regulate AV 
pathophysiology by modulating inflammation, remodeling or cell death. 
For ex vivo studies, fresh porcine AV tissues (n=9) were cultured in a 
shear stress bioreactor for 48 hours.For altered-shear studies, fibrosa 
was exposed to unidirectional pulsatile (FL: 0-80dyne/cm2) shear stress 
and ventricularis was exposed to bidirectional oscillatory (VO: +/-
5dyne/cm2). For side-specific studies, fibrosa was also exposed to 
bidirectional oscillatory shear stress. Following shear, total RNA was 
isolated from 3 pooled samples and expression of miRs was determined 
by qPCR (n=3). Altered-shear (FL vs VO) significantly (p<0.05) 
upregulated miR-181a and downregulated miR-199a and 214, indicating 
these miRs are shear-sensitive. Also miR-181a was significantly 
(p<0.05) upregulated in fibrosa exposed to oscillatory shear compared to 
that of ventricularis, showing side-dependency. In summary, miR-181a, 
199a and 214 are shear-sensitive but not miR-181b. MiR-181a is also 














Aortic valve endothelial cells (VECs) function in different heamodynamic 
environments. The influence of shear stress patterns on the 
biomechanical characteristics of VECs on each side of the valve has not 
been investigated. We assessed the relative expression of actin 
filaments and mechanical properties of VECs on intact porcine valve and 
cultured VECs which were exposed to aortic and ventricular shear 
stresses by a Cone-and-Plate machine. Immunofluorescent staining and 
western blot analysis of actin filaments revealed a great expression in 
VECs on the ventricular surface. Exposing the cells to the physiological 
or reverse-side pattern of flow did not influence the heterogeneous 
expression of actin on each side of the valve. By using the scanning ion 
conductance microscopy, measurements of membrane compliance of 
VECs demonstrated that VECs on the ventricular side (0.020±0.001 
µm/kPa) were significantly stiffer than those on the aortic side 
(0.032±0.002 µm/kPa). Moreover, the relative differences in the 
mechanical properties of VEC on each side of the valve were not 
affected by varying the pattern of shear stress exposed to the VEC on 
either side of the valve. Under aortic and ventricular flow, membrane 
compliances of VECs on the ventricular side were maintained at 0.004-
0.005µm/kPa, whereas those on the aortic side were retained at 
0.011µm/kPa. This study has shown side-specific differences in the 
biomechanics of VECs that is independent of the forces generated 
across valve's surfaces. These findings further highlight the 
heterogeneous nature of VEC and may have important implications 















Altered remodeling is often an early indicator of valvular heart disease, 
however its link with valve mechanics or structure is not well understood. 
Our previous work demonstrated that 5HTR2A and 5HTR2B expression 
was upregulated when valve interstitial cells (VICs) experienced 
elevated stress. Immunohistochemistry of normal and calcified human 
valves showed that 5HTR2A, 5HTR2B and FGF2 were highly expressed in 
calcified cusps, while FGF1 was expressed in normal cusps. Taken 
together, we hypothesized that VICs respond to altered mechanical 
stress by changing their matrix remodeling activities and that this 
feedback is mediated via 5HT and FGF2 signaling in valve disease. In 
the current study, we forced single VICs to self-assemble into rectangles 
with 1:3, 1:5, 1:7 aspect ratio, to simulate 0%, 10%, 20% cyclic 
mechanical loading, respectively.  After 48 hours, immunofluorescence 
showed strong expression of F-actin, FGF2, 5HTR2A, 5HTR2B, FGFR1 
and FGFR2 at increased stretch. Interestingly, we observed the 
localization of FGFR1 and 5HTR2A to actin cytoskeletal filaments while 
FGF2 localized to microtubule structures. We will quantify gene and 
protein expression in this model with the addition of serotonin and 
different combination of receptor inhibitors. Valves in a mouse model for 
hypertension and serotonin overload (3 weeks treatment) demonstrated 
increased leaflet thickening and thickness of collagen fibers as 
evidenced by picrosirius red staining. We expect our results to highlight 
the interplay between FGF and 5HT signaling in the progression of 
valvular heart disease and the key signaling molecules that can be 
















A synthetic scaffold for heart valve tissue engineering offers a high level 
of reproducibility, low risk of infection and easy to tailored architecture 
such as mechanical properties and porosity. However a purely synthetic 
scaffold suffers a major drawback in that it offers little or no biomimictic 
surface to direct cell adhesion, migration and function. Biomimitic 
peptides are often simple, short peptide sequences that can exert 
bioactivity. Through computer modelling we have designed and validate 
different peptide amphiphiles (PA) tails that enhance coating ability of 
the PA onto a synthetic polymer, poly ε-Caprolactone (PCL), which is 
commonly used as a tissue engineered scaffold. The PA platform offers 
a single polypeptide chain that contains both polymer anchoring site and 
functional peptide region for a simple method to coat PCL scaffold with 
specific bioactivity. In this study, we use collagen stimulating 
peptide/peptide amphiphiles (PA) consisting of hydrophobic alkyl tails 
and hydrophilic head that covalently bind to the hydrophilic active 
peptide regions. Transmission scanning microscopy shows that the PA 
are able to self assemble into nanofibers. Cell studies show that the PA 
has low toxicity and enhances collagen production in adipose derived 
stem cells between 6-13%. Further development of PA that confer 
desirable cellular functions represents an exciting step toward the 
construction of intelligent scaffolds suitable for a range of tissue 






















Non-coaptation of tissue-engineered heart valves (TEHVs) is due to 
cellular contractile forces and remodelling within the matrix, which act to 
decrease the overall size of the leaflets. We propose to address this 
problem by combining the advantages of fibrin gel as an autologous cell 
carrier material with the contraction-buffering capability of a freeze-dried, 
cross-linked collagen-glycosaminoglycan (CG) scaffold. The aim of the 
present study was to assess the contraction of the CG-fibrin scaffold 
(CGF) when seeded with human vascular smooth muscle cells (SMCs), 
and to develop a tri-leaflet TEHV scaffold using the same material. Disc-
shaped CG scaffolds (n=4) were cast and subsequently crosslinked 
using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. Cells were seeded 
into the scaffold at a density of 3,000cells/mm3 using a fibrin carrier 
material. A control group consisted of cell-seeded fibrin without the CG 
backbone material. After 7 days of culture, fibrin-only scaffolds 
contracted to 10% of their original diameter, while the CGF scaffolds 
maintained their original diameter. PicoGreen assay on the CGF scaffold 
showed a significant increase in cell proliferation after 5 days, while live-
dead staining revealed few dead cells. Masson's trichrome staining 
demonstrated that SMCs were homogenously distributed throughout the 
CGF scaffold and that CG and fibrin were still present after 7 days. 
Through the development of a mould and optimisation of freeze-drying 
and infiltration parameters, a tri-leaflet TEHV CGF scaffold was 
successfully produced. This CGF scaffold shows great potential for use 
as a HV scaffold due to its ability to maintain structural integrity and 













Bio-mimetic peptides are extremely useful to decorate bio-signals and to 
attract cardiac cells on scaffolds for tissue engineering (TE) heart valves. 
However, customizing the bio-mimetic peptides for cardiac TE and 
tailoring them to implant on the surface of the scaffolds require 
understanding of their structural properties such as stability and self-
assembly. Here, we use computational bioengineering to model bio-
mimetic peptides with unique design for collagen stimulation in TE 
construct and utilize molecular dynamics to study their structural 
properties. The modeling results signify that the studied bio-mimetic 
peptides form β-sheet for structural stability and self-assemble like 
twisted ribbons, in which, it is interesting to see the arrangement of 
collagen stimulation motifs as borders to attract cell receptors. The 
potential bio-mimetic peptides models are synthesised to examine under 
experimental conditions for ordered self-assembly, cell toxicity, collagen 
production and coating on polycaprolactone scaffold. These ongoing 
wet-lab experiments are essential to apply this novel design for TE heart 
valves. The structural basis from this studywill be helpful to design a 
multifunctional bio-mimetic scaffold for TE heart valves and to attract 













Scaffolding materials for tissue engineering should meet some basic 
requirements, e.g. being degradable, support cellular adhesion and 
provide adequate stimulation, i.e. growth factors (GFs). In this context 
immobilized GFs bear great potential and GF-mimicking peptides would 
be even more valuable. In this study we investigated the biological 
performance of LL37 - originally described as an antimicrobial peptide - 
as a VEGF-mimic. 
LL37 was covalently grafted to a gold surface as a model substrate, 
either directly or via polyethyleneglycol-mediated (PEG) coupling. 
Proliferation of endothelial cells (ECs) was monitored using the Electric 
Cell-substrate Impedance Sensing (ECIS) system, based on label-free 
detection by resistance measurements. 
PEG-immobilized LL37 was able to stimulate EC-proliferation over a 
period of 72 h whereas directly coupled peptide showed no activity. The 
mitogenic effect was comparable to soluble VEGF. 
LL37 exhibits multiple biological functions of which the VEGF-mimicking 
ability is currently under investigation. Conjugation of this peptide might 
contribute to the vascularization problem of tissue engineering scaffolds 
while circumventing the application of entire GF proteins. In this way 















The aim of this study was the development and evaluation of a new cell 
seeded bio-hybrid aortic valve scaffold based on human origin and 
synthetic materials. Scaffolds (n=6) were manufactured using 
decellularized homograft leaflets and polyurethane patches that were 
sutured together on a conventional CoCr-Stent. Fibroblasts (FBs) and 
endothelial cells (ECs) were isolated from saphenous vein segments 
and expanded in culture. Scaffolds were seeded with FBs (7.5x105 
cells/cm2), followed by static cultivation for 6 days. Subsequent EC-
seeding (7.5x105 cells/cm2) was realised under the same conditions. 
Pre-conditioning was performed by an exposure to pulsatile low-flow 
(750 ml/min) for 5 days in a standard incubator at 37°C and 5% CO2. 
Implantation was simulated by crimping the valve with an available 
crimping device followed by dilatation with a balloon catheter and finally 
exposure to higher flow conditions (1500 ml/min) for 2 days. Valve 
performance was documented by endoscopy. Samples were taken 
before and after each processing step, and analysed by scanning 
electron microscopy (SEM), immunohistochemical (IHC) and life-dead 
staining. SEM evaluation and IHC staining against TE-7 (FB-specific) 
and CD31 (EC-specific) proved the successful cell seeding process. 
Establishment of an extracellular matrix was detected by staining against 
collagen IV and fibronectin. The newly developed bio-hybrid scaffold 
showed excellent performance under endoscopic visualization and 
presented promising cell colonization characteristics, however, crimping 
and balloon dilatation induced significant cell damages. In summary, it 
seems that the crimping process has a big negative effect on biological 
















Polymeric heart valves (PHVs) have been investigated since 1960 but 
their success has been hampered by an overall lack of durability, due to 
leaflets calcification and thromboembolic complications. The aim of this 
work was to study a new elastomeric material for the development of a 
single-body PHV. 
CarboSil® (CS) was dissolved in THF/DMAc 1:1 (v/v) to obtain a 2% 
(w/v) solution. CarboSil® solutions containing 10% (CS10) and 30% of 
PDMS (CS30) were obtained by a reaction under stirring and nitrogen 
flow for 6 h at 82 °C. For each materials planar patches were obtained 
by a spray, phase-inversion technique on a rotating cylindrical mandrel. 
In vitro tests were carried out to evaluate: bio/hemocompatibility, 
calcification, hydrolytic degradation, oxidative degradation, 
environmental stress cracking (ESC) degradation, and mechanical 
properties.  
Materials extracts showed no cytotoxic effects on mouse fibroblasts 
respect to untreated cells. CS30 induced a lower in vitro platelets 
adhesion than the CS one. Coagulation times were similar for all tested 
materials. CS10 and CS30 showed less calcification spots compared to 
CS (SEM). IR demonstrated no significant differences among CS, CS10 
e CS30 samples after hydrolytic degradation. CS30 was less 
susceptibility to oxidative degradation and to ESC. No mechanical 
differences were found between all materials. A single-body PHV 
prototype, with an incorporated stent, was successfully obtained by 
spray, phase-inversion technique with CS30.  
CarboSil®-PDMS processed by the spray material deposition on a 3D 


















Tissue-engineered heart valves that contain living cells are associated 
with logistical hurdles. In contrast, decellularized xenografts and 
allografts lack growth and remodeling capacity and either risk 
immunogenic reactions and disease transmission or suffer from limited 
availability. Therefore, we recently introduced decellularized tissue-
engineered heart valves (dTEHVs), based on biodegradable synthetic 
materials and homologous cells, as an alternative off-the-shelf valve 
replacement. Subsequently, we studied the functionality and host 
repopulation capacity of such dTEHVs in non-human primate and ovine 
models up to 24 weeks. Remarkably, the valve leaflets became rapidly 
repopulated with endogenous cells, starting within 5 hours post-OP. 
Excellent in-vivo performance of dTEHVs was demonstrated up to 8 
weeks in the ovine model, where after mild to moderate insufficiency 
developed. The small valvular insufficiency was also detected in the 
non-human primates. Post-mortem the dTEHVs revealed mobile and 
thin leaflets, however, relative leaflet shortening was observed in the 
primates and beyond 8 weeks follow-up in sheep. Mechanical analyses 
of the ovine leaflets showed a trend towards increased anisotropic 
properties over time, resembling remodeling towards native-like valvular 
properties. Remodeling was confirmed by increasing collagen density, 
presence of elastic fibers, and endothelialized surfaces, starting in the 
valvular wall, going into the leaflets over time. To overcome the 
observed reduction in leaflet size, changes in valve geometry are 
necessary in order to improve physiological loading of the leaflets. 
Nevertheless, these homologous, non-immunogenic, off-the-shelf 
dTEHVs with good initial valve performance, rapid cellular repopulation 
and remodeling capacity have great potential as alternative to currently 














Currently used valvular prostheses lack growth potential. This is a major 
problem for young children that need staged interventions to 
accommodate growth of the valve with increasing risk of morbidity and 
mortality. 
Driessen-Mol et al.[1] demonstrated the unique regenerative capacity of 
decellularized tissue-engineered heart valves (DTEHVs) in vivo. Proper 
valve function was demonstrated up to 8 weeks, but was gradually lost 
toward 24 weeks. Loss in valve functionality was observed in 
accordance with increased host cell repopulation. Recent computational 
simulations by Loerakker et al.[2] showed that when the current valve 
geometry was subjected to hemodynamic loading, it resulted in radial 
leaflet compression rather than the expected radial extension. Therefore, 
we hypothesize that contractile host cell repopulation in combination with 
hemodynamic leaflet compression, eventually may have resulted in 
leaflet shortening and valve insufficiency. 
Based on the computational results, the valve geometry was adjusted to 
facilitate radial leaflet straining in diastole. Controlling DTEHV geometry 
has been challenging so far, because tissue compaction during culture 
always resulted in flattened leaflets. Therefore, a physical constraint was 
introduced in the bioreactor system to enforce curvature of the leaflets. 
During heart valve culture, cells compacted the leaflets around this 
insert, which guided the valvular geometry while allowing nutrient and 
oxygen supply to the valve. This resulted in excellent in vitro functionality 
of the valves, matching the exact imposed geometry. 
[1] Driessen-Mol et al., J Am Coll Cardiol., 2014 
[2] Loerakker et al., Journal of Biomechanics, 2013 













Clinically available tissue valves commonly employ the use of 
chemically-fixed tissues that present minimal recellularization potential 
and are prone to calcification. Utilizing an allogeneic, decellularized 
engineered tissue valve could potentially satisfy these shortcomings by 
enabling tissue maintenance and homeostasis due to their high 
propensity for recellularization. We present here a novel tissue-
engineered heart valve design based on a collapsing tissue tube (Cox et 
al, JTCS, 2005), using a decellularized engineered tissue tube. 
Tissue tubes with strong circumferential alignment were grown by 
fibroblast remodeling of fibrin gel over 5-7 weeks in vitro, including cyclic 
distension conditioning to promote collagen transcription and deposition, 
followed by decellularization.  When such tubes grown from ovine 
fibroblasts were implanted for 6 months as interpositional grafts in the 
sheep femoral artery, they exhibited complete endothelialization and 
recellularization with no dilatation, narrowing, mineralization, or immune 
response. 
  
When mounted on a custom frame (3-pronged crown), the tubular valves 
made from 22 mm diameter ovine tissue tubes performed well in 
pulmonary and aortic conditions of a pulse duplicator: >95% EOA, <5% 
regurgitant fraction, <3 mmHg systolic pressure drop. Pre-clinical testing 
of these valves is commencing. Performance of tubular valves made 
from human fibroblast-derived  tissue tubes is compared; like the ovine 
tubes, the human tubes also possess mechanical strength / stiffness in 
the 5 MPa range and mechanical anisotropy. 
  
A frameless version of this tubular heart valve that has potential for 
somatic growth and thus suitable for pediatric pulmonary applications is 
also presented, including pulse duplicator studies. 
  












CorMatrix has designed a tricuspid valve from small intestine 
submucosa (SIS) with the ability to remodel into patient tissue. This 
design demonstrated excellent functional results two years post-implant 
in an ovine model. An earlier feasibility study with 2-ply SIS yielded 
better results with more rapid remodeling. Thus, the study objective was 
to evaluate this valve design using different SIS configurations. Valve 
function and remodeling were evaluated at three months (n=14). The 
valve was sutured into a cylindrical sleeve (30mmX30mm). SIS 
configurations included 2-ply, 2-ply pressed, and 4-ply. The native valve, 
including chordae, was excised, distal end of the SIS valve sutured to 
the papillary muscles, and proximal end sutured to the annulus. 
Echocardiography and angiography evaluated in vivo valve function. 
Histology included H&E, von Kossa, and Movat. Immunohistochemical 
staining with Vimentin and SMA identified interstitial cells, and vWF and 
eNOS identified endothelial cells. Echocardiography and angiography 
showed complete coaptation of the leaflets with mild/no regurgitation. 
Grossly, explanted valves appeared to be significantly remodeled at 
three months. The 2-ply valves had consistent cellular infiltration and 
confluent endothelial cell lining. The 4-ply valves contained microscopic 
intracuspal thrombus and less consistent or less advanced cellular 
infiltration. The 2-ply pressed configuration had excellent results in some 
valves, but microscopic intracuspal thrombus in others. These results 
demonstrate reproducible function of this valve design and influence of 
SIS configuration on valve remodeling. The 2-ply valve, which 
demonstrated excellent results in an earlier feasibility study, was 
















Historically, tissue-engineered heart valves (TEHVs) have been 
designed to mimic the shape of the native valve to recreate the natural 
haemodynamics. This implies the fabrication of leaflets to ensure the 
unidirectional blood flow. However, the inadequate leaflets' functionality 
ultimately determined the failure of TEHVs in preclinical studies. Here 
we propose a tubular leaflet design as alternative to the classical design, 
abandoning the idea of mimicking the complex native leaflets' shape. 
Instead, a simple tubular tissue-engineered construct is sutured at three 
distinct sinotubular commissural points and along a circumferential line 
at the annulus level, so that it collapses inwardly and closes the conduit 
when exposed to diastolic backflow. The valve can be either implanted 
orthotopically in the aortic/pulmonary root by conventional surgical 
replacement or it can be sewn into a self-expandable nitinol stent for 
minimally invasive transcatheter delivery.  
The valves were moulded in fibrin gel embedding human umbilical vein 
cells and reinforced by a warp-knitted textile mesh for mechanical 
stability. After three weeks of conditioning in bioreactors, the valves were 
fully functional with unobstructed opening and complete closure. Tissue 
analysis showed deposition of oriented collagen I and III and a confluent 
endothelial cell layer on the surface of the valves. The valves underwent 
crimping for 20 minutes to simulate the catheter based-delivery, with no 
effect on their functionality, on the extracellular matrix organization nor 
on the mechanical properties. These results show the potential of the 
tubular leaflet design as an attractive alternative to the conventional 













Biological scaffolds have been assessed for tissue engineering 
purposes, however the lack of long-term stability due to degradation in 
some situations limits their use. Synthetic materials can overcome this 
issue by offering longer stability with slower degrading rates. We have 
previously developed a novel method to create synthetic anisotropic 
fibers that can promote cell proliferation and matrix production. This 
study aims to analyse the behaviour of the matrices in a dynamic 
environment where pulsatile pressure is applied. Poly ε-Caprolactone 
(PCL) aligned fibers made by using a jet spraying method were tested 
with and without human mesenchymal stem cells (hMSCs) using a 
pulsatile bioreactor. Aligned fibers are able to withstand pulsatile 
pressure with a gradient of 0-80 mm Hg for up to 3 weeks without 
ultrastructural damage as shown by scanning electron microscopy. 
hMSCs were dynamically seeded for 7 days within the fibres to ensure 
cell-spreading throughout the thickness as shown by DAPI staining of 
transverse sections. The seeded scaffolds were then moved into a 
bioreactor to test their durability. Pulsatile pressure was applied and 
maintained at a gradient of 0-80 mm Hg for a further 7 days to mimic 
aortic valve systemic conditions. Preliminary data show cells still present 
inside the scaffold after exposure to pressure synthesized more collagen 
than samples not exposed to pulsatile pressure. These results suggest 
that under systemic pulsatile pressure, jet sprayed anisotropic PCL 
fibres do not lose integrity and support cell function, proving to be good 



















Previously, we demonstrated in vivo that ice-free cryopreservation (IFC) 
reduced T cell infiltration heart valve leaflets compared with controls. We 
hypothesized that IFC human tissues will exhibit reduced allogeneic 
immune stimulatory properties compared with fresh untreated control 
grafts. Human engineered blood vessels (TEBVs) were generated by 
culturing smooth muscle cells on a polyglycolic acid scaffold, 
cryopreserved with an 83% formulation (DMSO, propanediol and 
formamide) and stored. Fresh and rewarmed, washed IFC TEBVs were 
compared by incubation with human peripheral blood mononuclear cells 
(hPBMCs) for 3 and 7 days. Proliferation was assessed by resazurin 
assay and cytokines by ELISA. Statistical significance was determined 
by t-test, p<0.05. There was no stimulation of hPBMC proliferation by 
IFC TEBVs. Significant proliferation of hPBMCs occurred with fresh 
TEBVs. Significantly lower IL-6, IFN-γ, TNF-α and IL-10 release from 
IFC groups was observed compared with fresh tissue groups. IL-2, IL-
12, and IL-18 release were not in either IFC or control TEBV groups. 
Additional culture controls with fresh and IFC tissues demonstrated that 
cytokines were not detectable without the presence of PBMCs. We 
conclude that ice-free cryopreservation of allogeneic TEBVs significantly 
reduces the hPBMC proliferative response and cytokine release (IL-6, 
IFN-γ, TNF-α and IL-10) compared with untreated, fresh TEBVs. The 
source of cytokines was the PBMCs not the allograft tissues. These 
results suggest that ice-free cryopreservation may be an improved 
method for processing and cryopreservation of allogeneic human heart 
valve and arterial tissues for surgical applications. Future studies will 

















It is not clear how tissue engineered materials for heart valvular 
substitutes change in hitogenesis after implantation. We are developing 
a novel autologous aortic valve (Biovalve), using simple, safe and 
economical in-body tissue engineering which is based on a tissue 
encapsulation phenomenon in the living body. In this study, we 
investigated key factors in hitogenesis when the Biovalve was implanted 
in a large animal model. 
Biovalves were prepared by 2-month embedding of the plastic molds in 
the subcutaneous spaces of goats. After extracting the molds and 
removing the plastic rods only, Biovalves were constituted from 
completely autologous connective tissues. We combined them with a 
metaric stent and implanted in the aorta in situ with transcatheter valve 
implantation technique. 
The Biovalve Stents were successfully implanted in the aortic postion. 
They were extracted 1, 2 or 5 months after implantation. The leaflets of 
the Biovalve kept their shape and elasticity even after 5 months and 
neither calcification nor thrombi were observed. Histological examination 
showed the cell migration inside the Biovalves' body and laminar 
endothelialization on the surface of the valve leaflets even in 1 month 
after implantation. Their histogenesis have gradually advanced in 5 
months, but were interrupted when the Biovalve tissues were not 
attached enough on the native vascular wall tissue. 
the Biovalve satisfied the higher requirements of systemic circulation in 
goats for 5 months with the histogenic potential that was mainly induced 















Mitral valve closure is preceded, during atrial systole, by reduced mitral 
annular (MA) size. This reduction requires little inward force from 
contracting atrial myocytes because the valve is open and left ventricular 
pressure (LVP) is low. But this annular size reduction, important to valve 
competence, is maintained by some inward-directed force during 
ventricular systole and the source of this force is not well understood. 
One possible candidate is contraction of the basal left ventricular 
myocardium pressing inward on the annulus which requires tight 
coupling between the MA and the basal LV myocardium. To test this 
possibility, MAseptal-MAlateral and MAseptal-LVlateral dimensions were 
computed from 4D marker data obtained every 16.7ms for 3 sequential 
beats in each of 12 ovine hearts. The group mean Pearson Correlation 
Coefficient between these dimensions for all data in all 12 hearts was 
0.59 (range 0.04 to 0.80), thus the LV myocardium is not tightly coupled 
to the MA. But basal LV dynamics did have a precise relationship to MA 
dynamics. In late diastole, the MA moved inward while the LV base was 
relatively fixed; in systole, the MA was relatively fixed, while the LV base 
moved inward. During isovolumic relaxation, the MA moved outward as 
LVP fell, while the LV base was relatively fixed. Thus the inward force 
maintaining the annular size reduction is LVP acting on the posterior 
leaflets; the LV pulls back, not presses in, on the annulus. Consideration 













Misexpression of collagens and glycosaminoglycans (GAGs) is a 
hallmark of aortic valve disease (AVD), and is frequently associated with 
TGFβ pathway abnormalities. We investigated the effects of exogenous 
TGFβ, pathway inhibition (Smad/canonical and ERK1/2/non-canonical), 
aging, and stretch, on aortic valve interstitial cells (VICs) regulation of 
ECM content and specifically, homeostasis of GAG hyaluronan (HA). 
VIC cultures from suckling (1-3 month old) and aged (2 year old) pigs 
were treated with TGFβ ± canonical (SB431542) and non-canonical 
(U0126) pathway inhibitors for 48hrs, under 0% or 5% cyclic strain. 
Secreted collagen, GAGs, and HA were quantified using 
biochemical/electrophoresis assays. Expression of aSMA (VIC activation 
marker) was assessed using RT-PCR. In suckling VICs, TGFβ elevated 
GAG synthesis and reduced collagen synthesis. In aged VICs, both 
collagen and GAGs increased with TGFβ addition in 0% and 5% strain 
conditions. Both inhibitors rescued collagen levels but not GAG levels, 
with or without TGFβ, for suckling VICs but not for aged VICs. TGFβ 
activated suckling VICs; quiescence was partially restored with U0126, 
but not SB431542. Neither inhibitor rescued cell phenotype for aged 
VICs. TGFβ increased HA secretion 3-5X into culture medium and 10X 
within the cell layer; SB431542 prevented HA retention in the cell layer 
but HA secretion into the medium was unaffected. Results suggest 
differential VIC regulation of ECM due to TGFβ and its inhibitors with 
biomechanical stimulation. We speculate inhibition of ERK1/2 activation 
reverses the defective regulation of valve ECM homeostasis, particularly 















We hypothesize that deriving the biomechanical state of AVICs in-situ 
using an inverse modeling approach will reveal more accurate 
information regarding AVIC adaptations to various stimuli. To achieve 
this, a novel, integrated numerical/experimental methodology was 
developed to estimate AVIC mechanobiological state in-situ. Flexural 
deformations of intact AV leaflet specimens were used to quantify the 
effects of AVIC stiffness and contraction at the tissue level. Next, we 
incorporated tissue micromorphology in a down-scale framework that 
simulates AVIC-Extracellular matrix (ECM) interactions as a function of 
layer location. AVIC size, shape, distribution and orientation were 
quantified from histological data from all three layers. A representative 
volumetric element was optimized statistically for each layer to represent 
the native 3D structure. The optimized RVE size in each layer defined a 
single mesh element within the macro model. Cellular inclusions and 
surrounding ECM were defined as neo-Hookean materials. Experimental 
flexure data from three different activation states (thapsigargin, basal 
tonus and hypertensive) were used in conjunction with the model to 
probe the effects of AVIC stiffness and contraction on the tissue level 
response. The computed  differences between the computed macro and 
micro stress was attributed to cell stiffness and contractile changes. This 
numerical/experimental methodology was be used to deduce AVIC 
properties under various pathophysiological conditions. We are currently 













Heart valve disease is a major cause of mortality and morbidity in the 
Western population. More than 25% above the age of 65 suffers from a 
form of heart valve disease. The only current therapy is the replacement 
of the diseased valve with a prosthetic valve. Little is known about the 
cellular and molecular mechanisms underlying the initiation and 
progression of heart valve disease. This is mainly due to the absence of 
a heart valve disease model, which allows manipulation of the 
environmental conditions of the valve in its normal position in the heart. 
We have adapted the existing Minitiature Tissue Culture System (Lieber 
et al., 2010) and created culture conditions supporting the initiation and 
progression of heart valve disease in the mouse aortic and mitral valve. 
Thickening of the leaflets, proliferation and activation of the valvular 
interstitial cells, disruption of the extracellular matrix organization are 
observed. In addition, we have findings that suggest the endothelial to 
mesenchymal transformation of the endothelial cells of the valves. This 
model allows the modification of the hemodynamic, chemical and 
metabolic conditions, which are main determinants of the valvular 
organization, and therefore, could provide major insights in the 


















Bicuspid aortic valve (BAV) is often complicated by thoracic aortic 
dilation. Since aortic diameter as a criterium for surgery is only decisive 
at population level, it would be valuable to have tailored risk stratification 
at patient level. Therefore, we investigated structural differences 
between the aortic wall of BAV and tricuspid aortic valve (TAV) and 
identified immunohistochemical markers predictive of aorta dilation in 
BAV. 
Biopsies of the ascending aorta of BAV (n=36) and TAV (n=23) both 
without (BA, TA) and with (BAD, TAD) dilation were compared. 
Differentiating and mature vascular smooth muscle cells, lamin A/C, and 
progerin were studied immunohistochemically and with western blot. 
Further an activation cascade was investigated, featuring c-Kit, 
phosphorylated c-Kit (pc-Kit), mmp9, Hif1alpha and eNOS ,to unravel 
possible differences within the BA group. 
BAVs showed significantly less expression of differentiated smooth 
muscle cells: αSMA, SM22α, calponin and smoothelin as compared to 
TAVs. Lamin A/C and progerin expression was significantly lower in BAV 
than TAV (p<0.05).  Progerin expression increased significantly in TAD 
as compared to TA. The activation cascade with pc-Kit as a keyfactor, 
was present both in a subset of patients with BA and BAD. 
Our study showed that the aortic wall with BAV is less well differentiated 
as compared to TAV. Phosphorylation of c-Kit plays a crucial role in 
aortic dilation in BAV rather than inflammation and accelerated aging 
seen in TAV. For the first time, a subgroup is distinguished in BAV 
patients without aorta dilation suggestive of a different state of 











Extracellular matrix (ECM) remodeling is one of the earliest hallmarks in 
the development of calcific aortic valve disease (CAVD). However, 
traditional histochemical analysis does not provide information about 
higher-order ECM structure, such as collagen fiber organization. 
Characterizing the dynamic behavior of these structures is important for 
not only understanding disease-related changes in valve architecture 
and its impact on valve mechanics, but also for potentially developing 
imaging approaches that allow earlier CAVD detection. We performed 
confocal second harmonic generation microscopy (SHG) on aortic 
valves from healthy and diseased humans and found numerous changes 
in collagen fiber architecture that were visible using SHG but not 
detectable via histochemistry. In contrast to the collagen-sparse 
spongiosa in healthy valves, diseased valves possessed randomly-
aligned collagen fibers throughout the leaflet mid-section, with a sudden 
transition to tightly and uniformly aligned collagen fibers in the fibrosa. 
Despite similar density, the fiber directionality in the diseased fibrosa 
was substantially different from that in the healthy fibrosa. Analysis of 
forward-scatter SHG intensities, forward/backward scatter ratio, and 
Monte Carlo modeling of the SHG data revealed additional differences in 
collagen fiber density, length, diameter, and crimping at different disease 
stages. Interestingly, there was low standard deviation of collagen 
organization patterns within both the healthy and diseased valve groups, 
which was unexpected given the heterogeneity of CAVD. This study 
advances our understanding of ECM remodeling in CAVD, and may 
provide a basis for use of SHG in the detection or evaluation of CAVD 



















Dezellularized valve allografts re-endothelialized with autologous 
endothelial cells (EC) from vessels or differentiated from peripheral 
blood have shown promising results. To circumvent this invasive, 
respectively, low-success harvest of EC, we utilized autologous umbilical 
cord blood EPC derived EC for re-endothelialization of ovine 
decellularized pulmonary valves (UCBEC-DPV) and compared them to 
those re-endothelialized with peripheral blood derived EC (PBEC-DPV). 
UCBEC-DPV and PBEC-DPV (n=6, each) were implanted orthotopically 
in sheep (Ø 72 kg, age 2 y). Umbilical cord blood was kept frozen until 
EPC isolation for re-endothelialization. Valve function was investigated 
at implantation and at explantation 8 months post OP by 
echocardiography. Cusps´ surface cell coverage was analysed by 
phalloidin stain. Cellular repopulation and matrix integrity was analysed 
by histological stainings, while the identity of cells in the matrix was 
characterized by immunological staining. 
One animal (UCBEC-DPV) did not recover from anaesthesia. No valve 
related problems occurred during implantation period. Valves exhibited 
no insufficiencies, cusps were thin and translucent at explantation time. 
Cusp surfaces showed no significant difference concerning cell 
coverage among groups. In both groups matrix repopulation was mainly 
limited to ventricular sides of cusps and to adventitial sides of valvular 
walls. Cells covering cusps revealed expression of vWF, eNOS, sm-α-
actin and sm heavy chain 2. 
Re-endothelialization with ECs from both sources showed to be equally 
beneficial for function and repopulation of valves with host cells. As no 
cell type revealed to be superior, cell source could be chosen 














Extracellular nucleotides have major impact on thrombosis, inflammation 
and immune responses, but their expression and activity is valve is 
poorly studied.  Normal aortic valves and calcified valves were analyzed 
for ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto-
5'-nucleotidase (CD73) gene expression and immunocytochemical 
localisation. Nucleotide metabolism was characterised by incubation with 
AMP and ATP in both cultured human aortic valve endothelial (VECs) 
and interstitial cells (VICs). In addition, the influence of ventricular and 
aortic side flow patterns on CD39 and CD73 was assessed. CD39 was 
highly expressed in VECs and VICs with reduced levels of expression in 
calcified valves. In contrast CD73 was more highly expressed in calcified 
regions of the valves. When the VECs were exposed to their 
physiological pattern of flow the activity of CD39 and CD73 increased 
significantly (p<0.05). In conclusion, ventricular and aortic flow could 
play an important role in ectoenzyme expression in endothelial cells. The 
presence of CD39 and CD73 in valves suggests that valve have the 
ability to degrade extracellular nucleotides, which may contribute to the 
protective effect of their degradation product adenosine against 























An increasing number of young patients are choosing bioprostheses for 
aortic valve replacement. In this context the Ross operation deserves 
renewed consideration as an alternative biological substitute. 
Reoperation rates after the Ross procedure and after bioprosthetic AVR, 
however remain a concern in these patients. 
We report freedom from reoperation after the Ross procedure and 
bioprostheses for different age groups. 
The reoperation rates of 1.925 patients (mean age 41.2 ± 15.3 years, 
1.444 male) from the German Ross registry with a mean follow-up of 7.4 
± 4.7 years (range 0.00 - 18.51 years, 12866.6 patient years) were 
analyzed and compared to bioprostheses in three age groups (Group I < 
40 years, Group II 40-60 years, Group III > 60 years). 
At 10 (resp. 15) years of follow-up freedom from reoperation was as 
follows: Ross Group I 83% (85%), Ross group II 90% (90%) and Ross 
group III 81% (81%). Bioprostheses had the following results: Group I 
51% (35%), Group II 63% (25%) and Group III 92% (81%). 
There is some evidence that at least in the first 10 and 15 years after 
aortic valve replacement the Ross procedure provides a lower 
reoperation rate in younger and middle-aged patients compared to 
patients with bioprostheses. This may be of interest to patients' or 














Evaluate the mid-term clinical and echocardiographic results of fresh 
decellularized versus cryopreserved decellularized pulmonary allografts 
for RVOT during the Ross operation. 
Between 2005 and 2013, 166 Ross operations were performed using 
SDS decellularized pulmonary valve allografts. Of these, 124 were fresh 
decellularized allografts (mean age = 30±15 years) (Group 1) and 42 
were cryopreserved decellularized allografts (mean age= 34±11 years) 
(Group 2).  Conduit dysfunction was defined as any peak gradient > 40 
mmHg or insufficiency grade III or IV. Comparisons were made with 
Kaplan Meier survival estimate and the mean of peak gradients over 
time by the unbalanced two way repeated measures ANOVA. 
Peak gradients at hospital discharge (Group 1 = 14±5 mmHg and Group 
2 = 10±5mmHg) and at the latest follow-up (Group 1 = 14±5 mmHg and 
Group 2= 17±13 mmHg) were similar between groups (p=0,78). Peak 
gradient >40mmHg was never present in Group 1 but in 3 patients in 
Group 2. Moderate or severe regurgitation was present in one case of 
each group. Freedom from conduit dysfunction at 6 years was 
significantly better in Group 1 (97% - CL95%, 85-99%) versus Group 2 
(85% - CL95%, 78-90%) (p=0,014) at six years. Reoperation due to SVD 
was needed in only one patient in Group 2. 
Fresh decellularized allografts were associated with better medium term 
results when compared to cryopreserved decellularized allografts for 
RVOT reconstruction up to six years of follow-up.  These results indicate 
that cryopreservation is unnecessary and may be even detrimental 



















Conventional aortic valve replacement(AVR) in the young, active patient 
represents a suboptimal solution, in terms of long term survival and 
quality of life. Aim of the present work is to present our multicenter 
results with the pulmonary autograft in young patient undergoing aortic 
valve replacement. 
Between 1992-2013, 1967 patients (1786 adults;41.6±15.1 years) 
underwentAVR with the pulmonary autograft principle in 9 centers. All 
patients underwent prospective clinical and echocardiographic 
examinations, annually. Mean follow-up was 7.7±4.8 years (range 0-23) 
with a total cumulative follow-up of 14571 years with 635 patients having 
a follow-up of at least 10 years. 
In-hospital mortality was 1.37%(n=26). Late survival of the adult 
population was comparable to the age and gender matched general 
population (observed deaths:90, expected deaths:70; p=0.439). 
Freedom from autograft reoperation at 5, 10, and 15 years was 97.8%, 
95.9% and 89.6% respectively whereas freedom from homograft 
reoperation was 98.4%, 96.6% and 94.6% respectively. Overall freedom 
from reoperation was 96.2%, 92.8% and 86.2% respectively. 
Longitudinal modeling of functional valve characteristics revealed a 
low(<5%) probability of a patient being in higher autograft regurgitation 
grades throughout the first decade. 
For the young, active patient requiring aortic valve replacement, the 
autograft principle results in postoperative long-term survival comparable 
to that of the age and gender matched general population and 
reoperation rates within the 1% / patient*year boundaries. The autograft 
principle for the treatment of the aortic valve disease in young, active 
patients who want to avoid the shortcomings of conventional prostheses 















There is continuing concern about the risk of long-term autograft 
dilatation following the Ross procedure. The objective of this study was 
to characterise the shape and function of neo-aortic root both in dilated 
and nondilated states. 
Among 108 Ross patients undergoing yearly echocardiographic 
assessment in our unit for 16.5 ± 1.9 years after operation (range 13 - 
20), 11 patients with dilated autografts (DG, >45mm, age 47 ± 10) and 
10 patients with non-dilated autografts (NDG, <45mm, age 59 ± 7) were 
consented for cardiac multi-slice cine CT. Dimensions and distensibility 
of the aortic root were derived from the cine-CT images, and were 
compared with 11 age-matched normal controls (age 47 ± 9). The aortic 
valve function was also analysed by echocardiography. 
Additionally to the difference in the sinus diameters between DG, NDG 
and C (50 ± 3 mm vs 41 ± 3 mm vs 31 ± 4 mm, p < 0.01), the non-
coronary sinus of the DG tended to have larger height than that of NDG 
and C groups. DG patients had similar distensibility compared to control 
(25 ± 14 vs 34 ± 14 MPa-1, p = 0.20) whereas NDG patients showed 
trend towards lower distensibility (13 ± 7 MPa-1). Echocardiographic 
data showed only 2 severe and 2 moderate regurgitations, with no clear 
correlation between regurgitation severity and sinus dimension. 
These data support the notion that the autograft root has similar physical 
properties to the normal aortic root despite significant dilation, which was 















Infundibular stenosis occurring in “tetralogy of Fallot” has been found to 
be a very challenging abnormality to repair. We replaced the pulmonary 
valve with a combination of decellularized allogenic valve together with 
autologous vascularized matrix (= AutoVaM) as patch material to 
enlarge the RVOT. 
RVOT reconstruction was performed in minipigs. A decellularized 
allogeneic valve conduit was used in place of the pulmonary valve and 
AutoVaM obtained from the small intestine with preserved vessels as a 
patch to enlarge the outflow tract. Control animals received non-
vascularized autologous pericardium instead. Valve function was 
analysed by MRI. At explantation 3 and 6 months post OP, phalloidin 
was used to visualize cell coverage on the cusp surface. Repopulation 
and ECM integrity were examined by histological stainings and cell 
identity by immunofluorescence stainings. 
Allograft developed more severe insufficiencies when combined with a 
pericardial patch as observed by MRI. The cell layer on the cusp did not 
cover more than ¼ of the ventricular surface at explantation. Matrix-
repopulation with cells was moderate in the valvular wall and minimal in 
the cusps´ base. Cells between valvular wall and cusps consisted of 
cells positive for vimentin and sm α-actin. Clusters of smooth muscle 
cells (sm α-actin and MYH11 positive) were still detectable 6 months 
post OP within AutoVaM patches but never in pericardial patches. Few 
Troponin-T-positive cells were found in the patches towards the 
ventricular anastomosis. 
Clinical outcome and MRI analysis showed a better outcome of valve 



























Young women wishing to become pregnant are choosing Ross operation 
for aortic valve replacement as an alternative to mechanical or biological 
substitute. But there are limited data on maternal and perinatal outcome 
of pregnancy. 
We report outcome of pregnancy after the Ross procedure. 
42 Pregnancies among 31 women (mean age at Ross operation 
25.0±6.1 years) with a mean follow-up of 10.5±4.8 years (range 2.5 - 
22.4 years, no lost of FU, no death) were analyzed. 
24 women gave birth to one child, 5 women to two, one woman to three 
and one woman to four children. One baby was a stillbirth. There have 
been five reoperations in three women (four homografts for SVD, one 
autograft for NSVD in combination with one homograft for SVD). Two out 
of these five reoperations have been after the birth of a child in two 
women due to SVD of the homograft in one patient and due to one 
autograft for NSVD in combination with one homograft for SVD in the 
other patient. Three reoperations have been in one patient before 
childbearing due to SVD of the homograft three times. In last FU after 
birth there has been non aortic valve-regurgitation or pulmonary valve 
regurgitation > II° in all women. 
Ross procedure seems to be a possibility for uncomplicated and 
















Valve-sparing aortic root prostheses with anatomically shaped sinuses 
(“sinus prosthesis”, Uni-Graft® W SINUS, Braun) imply near-
physiological conditions. Therefore, we sought to test their 
hemodynamics in comparison to straight grafts and volunteers by use of 
4D flow MRI. Scans of 16 patients after David operation (13 sinus 
prostheses: “SP”, 1f, 54±14y; 3 straight grafts: “SG”, 1f, 51±13y) and 13 
age-matched healthy volunteers (“Vol”, 11f, 55±6y) were examined at 3T 
(Philips Achieva) after written informed consent. Using GTFlow 
(GyroTools, CH) data were visualized with streamlines and particle 
traces. Occurrence and magnitude of secondary flow patterns (vortices, 
helices) in the thoracic aorta and its sinuses were graded and correlated 
with aortic geometry. 
Whereas sinus vortices in SP resembled those of Vol, SG revealed 
abnormally formed vortices aligned orthogonal to the vessel wall. Sinus 
vortices were graded small or medium in 91% (SP) and 98% (Vol) 
analysis of 6 datasets ongoing due to aliasing; In SG, 22% showed no 
sinus vortex, 78% only small vortices. Patients revealed more aortic 
secondary flow patterns than Vol (SP: 2.6±0.8, SG: 3.0±1.0, Vol: 
1.4±0.8; p<0.05), potentially due to steeper postoperative curvature 
angle. Round aortic arch configuration predominated in Vol (11/13) 
compared to cubic (SP: 8/13, SG: 2/3) and gothic (SP: 3/13; SG: 1/3) 
forms in patients. 
Near-physiological sinus flows in sinus prostheses is reassuring. The 
increased number of secondary flow patterns distal to prostheses, 
however, is hemodynamically of concern and should trigger follow-up 
studies and the discussion, whether curved grafts could mitigate those 












Durability of aortic valve sparing root reconstruction depends on root 
dimensions and leaflet stress. A new “Sinus prosthesis” imitates the 
anatomical root considerations (Unigraft® W SINUS,B. Braun 
Melsungen AG,Germany). Aim of this study is the evaluation of aortic 
valve hemodynamics after valve sparing root reconstruction with this 
prosthesis. 
In the first 38 patients (32 m/6 f; mean age 52±13.1 years; range 24-70 
years) who underwent valve sparing procedures (02/2009-04/2012) 
according to the David reimplantation technique using the new Sinus 
prosthesis (SP),aortic valve movement was examined 
echocardiographically and compared to 20 healthy controls (C). Opening 
and closing motion patterns as well as distensibility of the aortic root and 
function of the valve were studied. 
Aortic valve opening and closing characteristics were as follows: rapid 
valve opening velocity was comparable between groups (SP: 40.9±9.1 
vs. C: 36.8±21.9 cm/s;p=0.24), rapid valve closing velocity was faster in 
SP than in controls (26.4±11.0 vs. 14.6±13.9 cm/s;p=0.002). Percent 
change of diameter,as a parameter of distensibility,was comparable to 
controls at the level of annulus and sinutubular junction and lower at 
sinus level (3.2±2.7 vs. 4.7±2.6%,p=0.048). 
The new sinus prosthesis imitates the native sinuses with normal 
dimensions of the sinuses.Closing velocity of the cusps is faster after SP 
implantation than in native roots of controls. Distensibility is limited 
according to the material.The dynamic behavior of the AV after root 
reconstruction with the SP is not completely physiological 
yet.However,mid-term results of valve function are suitable.The aim 













Transcatheter Aortic Valve Implantation (TAVI) has rapidly become the 
preferred solution for high-risk patients.  However, despite the excellent 
short and medium term results, this approach has recently been 
associated with high rates of ischemic lesions and dementia.  In most 
cases, these cannot be directly correlated with catheter manipulation 
during implantation, or with the severity of calcification.  Hence, the 
source of the complications is reasonably to be sought in the flow 
perturbations produced by transcatheter valves.  In fact, contrary to 
surgical solutions, TAVI devices are positioned inside the leaflets of the 
diseased valve, which are widened into the sinuses of Valsalva, 
producing alterations of the phyisiological hemodynamics. 
In this work, in order to gain a better understanding of the fluid dynamic 
perturbations introduced by transcatheter valves, particle image 
velocimetry was used to measure the flow in a mock aortic root made of 
transparent silicone.  To isolate the effects of transcatheter valves, the 
operating valve was encased in a transparent cylindrical wall, mimicking 
the expanded native leaflets after TAVI.  The experiments were carried 
out in a pulse duplicator, under physiological conditions, using a fluid 
solution providing optimum refractive index matching with the root and 
dynamic viscosity similar to blood. 
Direct comparison of the mean flow dynamics indicated that TAVI 
produces stagnation regions at the bottom of the Valsalva sinuses, 
which may promote thrombus formation and contribute to ischemic 
lesions. The study also provides accurate estimates of local shear and 














The use of decellularized valved allografts shows promising results in 
replacement of the pulmonary valve. Here, we report about our clinical 
results of aortic valve replacement using decellularized aortic 
homografts (DAH) in children and adults.From February 2008 to 
February 2014, 34 patients with a mean age of 23 years (range, 0.19 to 
65) were prospectively assessed after aortic valve replacement using 
DAH. Mean time from homograft harvesting to implantation of DAH was 
46 days (range, 25 to 69). The mean DAH diameter was 23 mm (range, 
10 to 27). Mean extracorporeal circulation and aortic cross-clamp time 
was 211 and 120 minutes respectively (range, 113 to 397 and 64 to 180) 
using DAH for aortic root replacement, including coronary transfer. 
There was one early, none conduit related, death (3,5%). 
Echocardiography and magnetic resonance imaging were used for 
postoperative evaluation. None of the patients required re-intervention or 
conduit explantation so far. In two patients (7.41%) a moderate aortic 
valve insufficiency was seen, no severe valve stenosis was observed so 
far. No dilatation of the aortic root was seen, however the follow up is 
short so far (45 years in total, mean 1.5 yrs., max. 6 yrs). DAHs satisfy 
the requirements of the systemic circulation. For selected patients, DAH 














Elective ascending thoracic aneurysm (aTAA) repair is based on family 
history, connective tissue disorder, growth rate, but primarily size. 
Rupture/dissection carries a high mortality and occurs in many patients 
who had not met size criteria for surgical repair. Wall stress may be 
better predictor than size for adverse events, but cannot be directly 
measured in vivo, rather determined from finite element analyses (FEA). 
Current FEA models are fraught with assumptions that limit result 
accuracy. The purpose of this study was to develop the first patient-
specific aTAA model using in vivo magnetic resonance imaging (MRI) to 
assess wall thickness, material properties, and 3D-geometry. ATAA 
patient underwent 4D-flow DENSE MRI. Lumen geometry and wall 
thickness were used to create surface contour meshes of aTAA 
geometry. DENSE measured circumferential and longitudinal aortic wall 
strain and wall material property was derived using inverse analysis. 
Zero-stress geometry was derived using a novel fast pre-stress 
approach. Peak von Mises stress of FEA model with zero-pressure 
correction was 465kPa, while without zero-pressure correction the model 
predicted 272kPa. Average von Mises stress predicted by zero-pressure 
correction FEA model was 98±18kPa while that for non-zero-pressure 
correction was 86±16kPa. ATAA models in literature have not accounted 
for zero-stress configuration or patient-specific material property. We 
demonstrate that in vivo MRI can be used to obtain patient-specific 
parameters that significantly impact wall stress results. Future 
computational models that use wall stress to predict aTAA adverse 
events must take into account zero-stress geometry and patient material 















Myxomatous mitral valve (MMV) prolapse is the second most common 
heart valve disease and the leading cause of mitral regurgitation. The 
hallmark of myxomatous disease is an excessive accumulation of 
proteoglycans leading to thickened heart valve leaflets. Moreover, focal 
areas, which display chondrogenic features, are observed indicating that 
myxomatous disease processes mimic chondrogenesis. However, the 
underlying molecular mechanisms driving chondrogenic gene 
expression in diseased valves are still poorly understood. Therefore, two 
murine models with skeletal defects were examined as potential models 
of myxomatous disease. Osteogenesis imperfecta murine (Oim) mice 
have a spontaneous mutation in Collagen1a2 leading to altered collagen 
content and structure. Adult homozygous mice display thickened aortic 
valves primarily due to increased proteoglycan deposition as indicated 
by pentachrome staining. Sox9, Collagen 2 and Hapln1 also are 
increased. Similarly, mice deficient in Axin2, a negative regulator of 
Wnt/β-catenin signaling, also develop thickened proteoglycan-rich aortic 
valves with increased chondrogenic markers, including increased 
aggrecan expression. These markers are consistent with chondrogenic 
features observed in myxomatous area of human MMV. Interestingly, 
chondrogenic differentiation appears to occur also in MMV from patients 
with Marfan syndrome and in the Fbn1C1039G mouse model for Marfan 
Syndrome. Together these mouse models indicate that chondrogenic 
pathways are active in myxomatous disease and can be used for future 


















The initial pathogenesis of aortic valve disease is poorly understood. 
Proteoglycans are putative early therapeutic targets, as they mediate 
initiation of atherogenesis and surround calcified valvular nodules. We 
examined the impact of a mildly atherogenic diet on proteoglycan 
content/composition in the mouse aortic valve. 
Male C57Bl/6J wild-type mice were fed control or high-fat (HF) diets for 4 
or 16 months. Valve function was assessed by echocardiography, and 
matrix composition/morphology by (immuno)histochemistry. Cultured 
porcine aortic VICs were treated with/without 5 ng/ml TGF-β1 for 5 days. 
At 4 months, valve function was unchanged between diets (p = 0.75), 
and all leaflets were negative for αSMA, CD45, and ApoB. HF leaflets 
were distally thickened (+126%, p < 0.05) due to proteoglycan 
deposition (+110%, p < 0.01), not collagen accumulation (p = 0.87). Only 
versican was elevated in HF leaflets (+138%, p < 0.05), with no change 
in decorin (p = 0.69) or biglycan (p = 0.59). Differential proteoglycan 
expression was mirrored in culture: TGF-β1 elevated total proteoglycan 
synthesis (+114%, p < 0.05), but only versican mRNA was increased 
(+53%, p < 0.05) while decorin and biglycan were reduced (-105% and -
162% respectively, p < 0.01). By 16 months, HF mice developed 
impaired valve function with increased transvalvular velocity (+48%, p < 
0.05). HF leaflets were proteoglycan-rich, αSMA-positive, and fibrotic, 
with all leaflet regions (proximal/medial/distal) thickened vs. controls 
(+493%, +472%, +77% respectively, p < 0.001). 
Thus, diet-induced valve dysfunction is preceded in mice by early 
















Degenerative heart valve disease like aortic valve stenosis (AVS) is 
characterized by disorganization of fibers in the extracellular matrix and 
cell invasion. Currently most histological-based methods for 
characterization of AVS demand for extensive processing of extracted 
valve material with impact on tissue morphology. We present a novel 
approach combining coherent anti-Stokes Raman scattering (CARS), 
endogenous two-photon excited fluorescence (TPEF) and second 
harmonic generation (SHG) to characterize AVS on aortic leaflets from 
apoe-/- and wildtype mice. In addition optical coherence tomography 
(OCT) enables thickness measurements and 3D visualization of murine 
aortic valve leaflets dynamics. OCT demonstrated increased leaflet 
thickening from 30µm up to 80µm, aortic valve insufficiency and 
decreased opening angle in apoe-/- mice. TPEF illustrated decreased 
and fragmented elastin fibers (ventricularis), SHG showed increased and 
disorganized collagen fibers (fibrosa) and CARS displayed adipocytes 
infiltration in apoe-/- whereas the wildtype did not show any of those 
pathological changes.  
Using non-linear optical microscopy cusp constituents can be examined 
simultaneously, three-dimensionally and without extensive manipulation 
of the sample. These technologies using high resolution imaging 
methods require no staining procedures, enable the analysis of the 















Elective ascending thoracic aneurysm (aTAA) repair is based on family 
history, connective tissue disorder, growth rate, but primarily size. 
Rupture/dissection carries a high mortality and occurs in many patients 
who had not met size criteria for surgical repair. Wall stress may be a 
better predictor than size for adverse events, but cannot be directly 
measured in vivo, rather determined from finite element analyses (FEA). 
FEA analysis of aortic stress faces many unique challenges. Reference 
(unloaded) geometry of aortic wall can't be readily measured; in vivo wall 
material property is often unknown. In this work we implement novel 
techniques to address these challenges. 4D flow MRI imaging was used 
to measure patient specific aortic blood flow information and 
displacement encoding with stimulated echo (DENSE) MRI was used to 
measure cyclic aortic wall motion. Aortic lumen geometry was contoured 
from MRI images and was used to create a numerical model of the 
aTAA. DENSE measured wall motion was used in an inverse analysis to 
characterize aortic material property. Reference geometry of the aortic 
was derived using a novel pre-stress approach. These patient specific 
aortic wall characteristics were then used to conduct a fluid structure 
interaction (FSI) simulation to calculate the in vivo wall stress. In vivo 
blood flow conditions measured from the 4D MRI were used as inlet 
boundary condition. We achieved unprecedented level of patient 
specificity in terms of in vivo aneurysm wall stress prediction. Further 
work on validation could pave the way for clinical applications of aTAA 













Tissue engineering a complete mitral valve substitute is challenging 
because of the anatomical complexity of the native valve and the high 
load conditions it has to withstand. Recently we realised the proof-of-
principle of the first tissue-engineered, fibrin-based, textile-reinforced 
mitral valve - TexMi - recapitulating the main anatomical features of the 
native valve i.e. the annulus, the asymmetric leaflets and the chordae 
tendineae, a crucial element to preserve the ventricular pumping 
efficiency which is, however, disregarded in the commercial available 
(non-viable) substitutes. The TexMi valve relies on a hybrid scaffold 
consisting of fibrin gel as a cell carrier and a warp-knitted mesh that 
defines the 3D geometry and provides mechanical stability. Here we 
present the second generation of the TexMi, with a load-optimised textile 
co-scaffold and improved design with four fully tissue-engineered 
chordae tendineae to be sutured at the papillary muscles. The valves 
were moulded with human cells isolated from the vein of the umbilical 
cord and cultivated under dynamic conditions over three weeks. 
Immunohistochemical staining showed the presence of aligned collagen 
fibres which appear striated in transmission electron microscopy. The 
collagen content was approximately 50% of the content found in the 
native mitral valve and the burst pressure reached 1000 mmHg. The 
considerable extracellular matrix formation and the high burst strength 
are encouraging results towards the realisation of a living prosthesis 
















We developed a novel pericardial based tissue (CALP) for bioprosthetic 
and tissue engineered heart valves. The influence of its material 
properties on blood flow, as well as its fluid structure interaction when 
fixed and decellularized for bioprosthetic valve manufacture were 
numerically simulated. Glutaraldehyde fixed and decellularized CALP 
was compared to that of Glutaraldehyde (Glu) fixed and decellularized 
bovine pericardium (BP) and porcine (PV) heart valve leaflets. Tissues 
were fixed in 0.6% Glu and stored in 0.2% Glu for testing. A two-
dimensional fluid structure interaction was modeled using Comsol 
Multiphysics finite element package (version 4.4, Comsol Ltd., London, 
UK). Calculated values for Young's modulus from uniaxial tests were: 
10, 8, 8 and 5 MPa for fixed PV, BP and CALP and decellularized CALP, 
respectively. The calculated Young's modulus of decellularized BP and 
PV was close to their fixed samples (approximately 8 and 10 MPa), and 
hence, simulations were not performed for these samples. Maximum 
valve opening was calculated as 82.26,74.52,71.13% of annulus 
diameter, for decellularized and fixed CALP and fixed PV, respectively. 
The time of maximum valve opening was similar (13.17,13.01,13.02% 
cardiac cycle). The peak pressure gradient was 0.49,0.51 and 0.53kPa, 
and peak Von Mises stress was 0.47,0.68 and 0.78MPa, for 
decellularized and fixed CALP and fixed PV, respectively. Peak shear 
rate was 21.13,18.68 and 16.67×1031/s. CALP could be considered as a 
superior alternative for valve fabrication as fixed CALP opening and 
structural behavior were similar to BP and decellularized CALP showed 












Substrate properties (physical and biochemical) as well as external 
mechanical and soluble chemical cues are important 
microenvironmental factors for directing the differentiation of bone 
marrow mesenchymal stromal cells (bmMSCs) in vitro.  Select 
combinations of these factors have been applied to bmMSCs (mostly in 
2D) for the purpose of heart valve tissue engineering. However, the 
integration of environmental factors in 3D culture has yet to be 
appropriately considered, despite being necessary for functional valve 
tissue development. To address this, we sought to characterize and 
validate a 3D screening platform that enabled the combinatorial 
assessment of chemical and stiffness factors affecting bmMSC viability, 
morphology and differentiation to a valve phenotype. Human bmMSCs, 
encapsulated in 4 –11 wt% (5–30 kPa) polyethylene glycol norbornene 
(PEG-NB) hydrogels, were cultured for 1 week.  Viability and 
morphology of bmMSCs were assessed as a function of polymer wt% 
and RGD concentration. Factorial central composite designs modeled 
the viability and morphology responses, demonstrating an optimal wt% 
and RGD concentration for maximal viability and spread 
morphology.  Separately, the effect of polymer wt% on the promotion of 
a synthetic valve phenotype (indicated by enhanced α-SMA staining) 
was investigated by supplementing media with 5 ng/mL TGF-β1 for 1 
week. The intensity of α-SMA staining significantly increased 1.6 fold in 
response to TGF-β1 treatment in both 4.7 and 7.5 wt% PEG-NB gels, 
but remained constant for 10.3% gels. This study highlights a novel 
platform with which to  identify specific aspects of the 3D valve 
















Scaffolds are main components of the proposed model of the tissue 
engineered heart valve (TEHV), which provide mechanical support, and 
guide cell growth and tissue formation. Thus, we investigated the 
compatibility of parylene C (PC) for use as scaffolds in TEHV by 
studying its biocompatibility and mechanical properties. Plasma oxidized 
PC slides were coated with type I collagen or fibronectin, and their 
adsorption was estimated by protein staining. To investigate the 
compatibility of PC with valve cells, porcine pulmonary valve endothelial 
and interstitial cells were grown on plasma oxidized PC with different 
types of ECM coating and their adhesion, viability, apoptosis, and 
phenotype were determined. Also, the mechanical properties of PC were 
measured and compared to porcine aortic valve, and the effect of film 
thickness on the mechanical properties was studied. PC showed 
compatibility with protein adsorption, and valve endothelial and 
interstitial viability and phenotypic expression. In addition, PC exhibits 
high yield strength and ultimate tensile strength, indicating its high 
resistant to fracture and plastic deformation. All of these properties 
indicate that PC could be suitable for use as scaffold for tissue 
engineered heart valves. The high stiffness of this material could be a 














Synthetic scaffolds for tissue engineering have proven to be good 
alternative to biological ones due to their flexibility in the manufacturing 
process and their controllable biodegradability. However, they lack 
biological cues for improved cell adhesion, migration and function. Poly 
ε-Caprolactone (PCL) films and aligned PCL fibers were coated with 
Dendri-Graft Poly-L-Lysine (DGL) and RGD peptide to investigate the 
effect on human mesenchymal stem cells migration and 
proliferation.  Films and aligned fibers were coated with DGL-bound 
RGD peptide and compared with uncoated scaffolds. Cells were 
incubated for 15 minutes or 2 hours, stained with DAPI and phalloidin to 
quantify cell numbers and cell adhesion by means of total cell area. After 
15 minutes incubation cell adhesion was higher when the DGL was 
bound to RGD peptide compared to both uncoated scaffolds or DGL 
only coated. This difference was even greater after 2 hours. Using 
specially designed chamber slides, a cell free area was created on 
surface of PCL fibers to study cell migration. Preliminary results show 
that even in a 3D structure the DGL-RGD coating improves cell 
migration by a faster cell growth/migration rate toward closing the gap 
compared to uncoated fibers. The use of DGL and extracellular matrix 
mimicking peptides such as RGD, could prove to be a good strategy to 














Implantation of xenografts leads to graft rejections. So far the αGal 
epitope was identified as strongest xenoantigen present on non-human 
grafts. Carbohydrates in general are believed to be xenoantigens, since 
the glycocalyx is species-specific. To address and circumvent the limited 
availability of human decellularized heart valve matrices for heart valve 
replacements in future, we investigated the removal of glycocalyx 
structures of porcine pulmonary heart valves (PPHV) by decellularization 
and glycolytic treatment. 
PPHV were decellularized by different detergent-based protocols and 
enzymatically treated by PNGase F. Potential carbohydrate removal was 
investigated by histochemistry using isolectin B4 (IL-B4) staining αGal 
epitops, wheat germ agglutinin (WGA) staining N-acetylglucosamines, 
datura stramonium lectin (DSL) staining β- 1,4 linked N-
acetylglucosamines and N-acetyllactosamines, and ricinus communis 
agglutinin I (RCA I) staining N-glycosides. Samples decellularized only 
served as controls. 
All lectins stained native PPHV, whereas a reduced lectin stain was 
observed on decellularized PPHV matrices in dependence of the 
decellularization protocol used. Compared to native tissue, 
SDS/TritonX100 reduced IL- B4 but not WGA, DSL, or RCA I. The other 
protocols reduced IL-B4, WGA and DSL stains. PNGase F abolished IL-
B4, WGA, and DSL stains independent on the type of decellularization. 
Thus, decellularization per se reduced αGal whereas decellularization by 
SDS/Na-deoxycholate and TritonX100+SDS, but not by 
SDS/TritonX100, additionally led to a removal of N-acetylglucosamines. 
Cleavage of GlcNacβ(1-N)Asn sites by PNGase F eliminates detergent-
independent carbohydrate structures like αGal and N-
acetylglucosamines. In summary, detergent based decellularization 
followed by PNGase F treatment resembles an efficient way to remove 












Calcific Aortic Valve Disease (CAVD) affects >2% of the population over 
the age of 65, for whom the only clinical therapy available is valve 
replacement surgery. Furthermore, the underlying pathogenic 
mechanisms of CAVD, which could serve as potential therapeutic 
targets, remain unknown. Klotho-null mice exhibit accelerated aging and 
aortic valve calcification similar to human CAVD. Notably, 
phosphorylation of Smads1/5/8, Bone Morphogenetic Protein (BMP) 
pathway effectors essential for bone calcification, is detected prior to the 
onset of calcification and later localizes with calcified nodules in Klotho-
null aortic valves. Our hypothesis is that activation of the BMP-
pSmad1/5/8 signaling cascade promotes aortic valve calcification in 
CAVD. Our preliminary studies demonstrate that osteo-chondrogenic 
factors are significantly increased in Klotho-null aortic valves, and 
pSmad1/5/8 activation precedes their induction in the region of the valve 
where calcification occurs. Moreover, increased BMP2/4 ligand 
expression is detected prior to, as well as during, calcific nodule 
formation. Together these data support an active role for BMP signaling 
as a critical mechanism in the development of CAVD. Our ongoing work 
includes: 1) Identifying the requirements for the BMP pathway in aortic 
valve calcification in vitro, and 2) Determining if BMP pathway inhibition 
















Calcific aortic valve disease is paradoxically correlated with osteoporosis 
in humans. Hyperlipidemia has been independently linked to both of 
these pathologies, and may represent a unifying causative factor 
between these two conditions. We examined this relationship by feeding 
male C57Bl/6J wild-type mice a control or a high fat (HF) diet (58.7% 
kcal from fat, cholesterol < 0.1% w/w) for 16 months ad libitum. 
Echocardiography was used to examine valve function, and blood 
testing determined serum cholesterol levels. Mouse bone mineral 
density (BMD) was measured using a Piximus bone density scanner. 
Overall weight of the HF group was 45% (p < 0.001) higher than the 
control, indicating obesity, and corresponded with elevated non-HDL 
cholesterol levels (+62%, p < 0.05). This coincided with the onset of 
valvular dysfunction, with a 48% increase in transvalvular velocity (p < 
0.05). The BMD of mice on the HF diet was reduced in the femur, 
humerus, and whole skeleton by 7-16% (p < 0.05 vs. control diet). Bone 
mineral content in HF mice was also reduced 23-24% from controls (p < 
0.001). The whole-body and femoral BMD was inversely correlated (r2 = 
0.43 - 0.49, p < 0.01) with transvalvular velocities in all mice. Overall, our 
results support the notion that mild hyperlipidemia leads to both valve 
dysfunction and altered bone metabolism in obese mice. Further 
investigation of the paradoxical progression of cardiovascular disease 
with osteoporosis under hypercholesterolemic conditions should be 











Glutaraldehyde is commonly used to crosslink the collagenous matrix of 
pericardium leading to increased durability and reduced  antigenicity of 
bioprosthetic heart valves. Structural valve deterioration due to 
calcification is the primary failure mode in these valves. Calcification is 
believed to be caused by multiple factors with glutaraldehyde as one of 
the major factors. Anti-calcification technologies have been developed to 
address this specific factor, yet the mechanism is still not completely 
understood. 
The objective of this work is to describe the amount of free aldehyde 
groups in glutaraldehyde-fixed bovine pericardium used for bioprosthetic 
heart valves and how it relates to in vivo interactions such as 
calcification. The concentrations of residual aldehyde groups found in 
bovine pericardium were determined by a novel test 
method.  Glutaraldehyde fixed tissue contained a high amount of free 
aldehyde groups, while tissue produced using GLX, an advanced 
integrity preservation technology which permanently caps residual 
aldehydes, contained an 88% reduction in aldehyde values. Calcification 
studies showed significantly higher calcification in tissue containing high 
concentrations of aldehyde residuals compared to low aldehyde 
residuals, with a 99.4% reduction in calcium for GLX tissue. The 
relationship between aldehyde levels and calcification potential of 
bioprosthetic tissue may be used as a tool for explaining the mechanism 













Calcific aortic valve disease (CAVD) is the third leading cause of heart 
disease in adults. It has been hypothesized that therapeutically stopping 
the formation of microvessels during early CAVD could prevent the 
pathological progression of the disease. However, the lack of 
understanding of valve cellular pathology has stymied discovery of 
potential treatments. Pericytes have been localized histologically along 
the exterior of these microvessels, but it is unknown whether these cells 
are derived from valve interstitial cells (VICs) or if VICs can differentiate 
into a proangiogenic pericyte phenotype. Therefore this study 
investigated the perivascular potential of VICs to stabilize valve 
endothelial cell (VEC) angiogenesis in a matrigel model and investigated 
potential VEC/VIC signaling pathways controlling their organization 
using small molecule inhibitors. Control vascular derived endothelial and 
pericyte cell lines formed stabilized networks in the model, but valve 
interstial cells collapsed valve endothelial cell network formation over 24 
hours into spheroids. Interestingly after spheroid formation, VICs began 
to promote valve endothelial cell sprouting into the matrix and were 
found wrapped around the VECs. These behaviors are suggesting both 
a pericyte-like and invasive phenotype for the VICs. This process was 
found to be Rho Kinase, protein kinase C, TGF-B, and Tie2 dependent 
and to be VEGF, NOTCH, NO, and PDGF independent at the 
concentrations tested in this study. The results of this study align with 
current hypothesises of the pathology of CAVD and offer new insights 












Utilizing both overexpression and extracellular application, we aim to 
target MG53, an essential cell membrane repair protein, to valvular cells 
for treatment of tissue injuries associated with valvular heart disease 
(VHD). Our group has identified MG53 as an essential component of the 
cell membrane repair machinery. Membrane repair is important to 
maintain normal cellular physiology, and disruption of this process can 
result in disease in a number of different tissues. With the four heart 
valves experiencing a tremendous amount of mechanical stress, we 
have utilized microelectrode needle penetration and glass bead damage 
assays to assess the ability of MG53 to protect valvular interstitial cells 
from physical injury. Furthermore, we have begun calcification studies to 
investigate the ability of MG53 to protect against inflammatory and 
osteogenic changes associated with VHD. To date, we have observed 
MG53-mediated protection against membrane damage through both live 
cell imaging and LDH release. With preliminary results, we have also 
noted MG53-mediated protection against changes in osteogenic gene 
expression after LPS treatment. Ongoing tests will further characterize 
the mechanisms of protection in valvular cells and assess the effects of 
MG53 in in vivo models of VHD. We anticipate that, once all of our aims 
are completed, our experiments will greatly contribute to the study of cell 
biology, regenerative medicine, and cardiovascular disease, the number 














Activity and nuclear vs. cytoplasm localization of the transcriptional co-
factors YAP (Yes-associated protein) and TAZ (PDZ-binding motive, 
WWTR1) have recently been associated to ECM stiffness e.g. in 
mammary epithelial cells, mesenchymal stem cells and cancer cells. 
Therefore these factors may represent key mediators of cell 
differentiation in response to ECM elasticity and cell shape. Accordingly, 
it has been presented that activity and localization of YAP/TAZ was 
under control of RhoA and the functional state of the actin cytoskeleton 
independent of Hippo kinases. Since mechanical cues reportedly affect 
structure and function of aortic valves this study aims at potential roles of 
YAP and TAZ as mediators of mechanotransduction. 
The expression of YAP/TAZ was analyzed in valvular interstitial cells 
(VIC) and quantified after culturing on soft gels with different stiffnesses. 
The total expression level of YAP and TAZ protein was elevated when 
VICs were cultured on surfaces with an elastic modulus of 25 kPa 
reflecting the matrix stiffness in fibrotic valves. On soft gels reflecting the 
stiffness of healthy valves (8 kPa) the protein expression was 
significantly lower. 
Whereas the localisation was not clearly correlated to matrix stiffness 
immunofluorescence experiments revealed a partially co-localisation of 
YAP to fokal adhesion kinase on collagen coated stiff matrices. 
Aims of the project are now to investigate signaling cascades of cell-
matrix interaction and/or stress fiber formation in relation to YAP as well 
as TAZ expression and localisation in VICs to define the relevance of 













BioGlue® Surgical Adhesive is approved for use in cardiac, vascular, and 
pulmonary surgery, as an adjunct to standard methods of repair (such as 
sutures, staples, electrocautery, and/or patches) to bond, seal, and/or 
reinforce soft tissue. This study evaluated the potential mechanical 
effects of BioGlue when applied to reinforce a suture line surgical repair 
of a valved aortic conduit. 
A defect was created in six aortic conduits, each conduit being bisected 
by a single incision just above the sinus. A 4-0 Prolene running suture 
line was then used to reattach the two halves of the conduit. BioGlue 
was applied to the suture line of three conduits. The remaining three 
conduits did not receive BioGlue. 
The physiological motion of the conduit was simulated using a Dynatek 
Heart Valve Tester. All conduits were loaded into the tester and cycled 
at approximately 200 cycles per minute with a closure load of 100 
mmHg. 
Daily inspections were performed to assess any changes to the surgical 
repair of each conduit. Visual examinations show the suture underneath 
the regions where the BioGlue had been applied to remain intact and in 
its original condition. There was no impact on suture performance as a 
result of BioGlue application over 60 million cycles. The suture material 
and tissue showed no signs of dehiscence, suture fracture, fraying, 














Fibrin is a promising scaffold material for tissue engineered heart valves, 
as it is completely biological, allows for engineered matrix alignment, 
and is able to be degraded and replaced with collagen by entrapped 
cells. However, the initial fibrin matrix is mechanically weak, and 
extensive in vitro culture is required to create valves with sufficient 
mechanical strength and stiffness for in vivo function. Cyclic stretching 
has been shown to increase collagen production by cells entrapped in a 
fibrin scaffold, accelerating the strengthening of the tissue and reducing 
the required culture time. However, the entrapped cells adapt to 
constant amplitude cyclic stretching, suggesting that some perturbation 
to a constant amplitude regimen may maximize the benefit.1-3 In this 
study, intermittent cyclic stretching (alternating stretching and rest) and 
incrementally increasing strain amplitude cyclic stretching were explored 
to overcome this adaptation and accelerate collagen production. Using a 
Flexcell Tension System, the effects of constant amplitude, intermittent, 
and incrementally increasing amplitude cyclic stretching regimens were 
investigated for neonatal human dermal fibroblasts entrapped in a fibrin 
scaffold. The cellular response was studied at the signaling level by 
monitoring the extracellular regulated kinase (ERK) and p38 pathways 
and at the gene transcription level by monitoring collagen transcription. 
Total collagen content and tensile properties of the resulting tissues 
were quantified. Collagen production was accelerated using an 
optimized cyclic stretching regimen. 
  
Funding: NSF Graduate Research Fellowship and NIH/NHLBI 
HL107572. 
  
1Paxton JZ, Tissue Eng. Part A 2012, 18(3-4):277-84.  
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In this work, we present a method for determining the functional 
properties of heart valve leaflets from non-invasive imaging techniques 
such as ultrasound and CT. The novelty of present approach is the use 
of collagen fiber maps to constrain the optimization and the use of a 
coupled surface fitting/in-plane strain approach to obtain new information 
for structural modeling of valve leaflets. As a first step, we use in-vitro 
experimental data from porcine bioprosthetic heart valve emulating an 
aortic valve put in a flow loop. The leaflet was imaged at three different 
static transvalvular pressures of 40, 80 and 120mm Hg using surface 
markers and dual-camera setup. This highly comprehensive data set 
with high resolution, marker positions at multiple pressures, valve 
specific fiber architecture and biaxial data was ideal for this study – to 
design the inverse model, validate it and calculate it’s sensitivity to 
various input parameters and optimization constraints. This information 
when combined with the inverse model presented in this work will lead to 
an in-vivo assessment tool for heart valves and help diagnose problems 
in the mechanical functionality at an early stage. Additionally, this 
approach will have the potential to serve as a general-purpose in-vivo 
assessment tool for heart valves – for evaluating the performance of 
replaced prosthetic valves as well as monitoring the progression of valve 
diseases. 














The mitral valve (MV) is one of the four heart valves which locates in 
between the left atrium and left ventricle and regulates the unidirectional 
blood flow and normal functioning of the heart during cardiac cycles. 
High-fidelity computer simulations provide a means to connect the 
cellular function with the organ-level MV tissue mechanical responses, 
and to help the design of optimal MV repair strategy. We present here 
the details of our first steps to create state-of-the-art of mitral valve 
modeling techniques, with an emphasis on what is known and 
investigated at various length scales. A modified left heart simulator was 
used for acquisition of the in-vitro mitral valve deformations at stress-free 
(referential), pressure loaded (~30 mmHg) and fully loaded (~70 mmHg) 
states. The segmented MV geometry at each state was imported into 
Geomagic Studio for generation of the corresponding finite element 
model. The 3D locations of the key points for representation of the MV 
chordae tendineae, such as MV PM attaching points, chordal branching 
points, and MV leaflet attaching points, were quantified for realistic 
reconstruction of chordae tendineae (297 three-dimensional truss 
elements). Moreover, spatially-varied and anatomically accurate MV 
leaflet thicknesses were determined from the Micro-CT data.  Next, 
collagen fiber micro-structural information was mapped onto the finite 
element model. The numerical predictions of the deformed geometry 
agreed well with the in-vitro experimental data, with the total 
displacement errors. We thus conclude that the improved accuracy of 
the current mapping techniques do indeed provide more accurate 
modeling results of the MV. 
  















There does not currently exist a means to evaluate and predict in vivo 
bioprosthetic valve response to long-term cyclic loading and blood 
contact interactions. Herein, we present a novel, integrated 
numerical/experimental technique to assess BHV biomaterial response 
in vivo in a completely device independent manner. GLUT treated 
porcine aortic valve leaflets are cut into shape and implanted in the 
anterior mitral valve leaflet of Dorset sheep. To explore the stress 
induced change in configuration, we implanted the PAV patch in 2 
different orientations: with the circumferential direction of the patch 
aligned to the circumferential direction of the mitral valve (C-C aligned), 
and with the circumferential direction of the patch aligned to the radial of 
the mitral valve (C-R aligned) thus interchanging the loading boundary 
condition in the circumferential and radial direction of the patch. To 
quantify the in vivo deformation and subsequently determine the in vivo 
stress, 4 sonocrystals are placed at the corners of the implanted patch, 
with an additional one at the center. An inverse finite element model is 
applied to the implanted patch using shell elements. After four weeks in 
vivo, the tissue was explanted and further evaluated for mechanics and 
microstructure. Results demonstrate that when compared with the 
original cross-linked material, the patch implanted in the C-C orientation 
exhibited a nearly identical stress-strain response when subjected to 
biaxial mechanical testing. However, the patch implanted in the rotated 
C-R orientation was drastically increase in stiffness and exhibit 
significant permanent creep along the radial direction of the patch. 














Valve endothelial cells (VECs) have been demonstrated to have a role in 
the regulation of the mechanical and biological integrity of the valve. As 
part of tissue engineering of heart valve, endothelial cell (EC) source is 
required that will match VECs in terms of the ability to respond to the 
flow patterns found on the aortic and ventricular surface of the valve. 
This study focuses on using adipose-derived stem cells (ADSCs) as a 
potential source of VECs and differentiating them into side-specific 
VECs by aortic and ventricular shear stress patterns. After stimulation 
with endothelial media, VEGF and side specific shear stress, ADSCs 
were positively stained for CD31, vWF and NOS III, and exhibited the 
ability to take-up low-density lipoprotein.  Semi-quantitative analysis of 
the level of the staining demonstrated that the aortic shear stress 
significantly increased the expression of NOS III (10.25 fold) and SMαA, 
(6.52 fold) as compared to the static control, whereas the ventricular 
shear pattern does not induce the same effects (n=3). These studies 
reveal that ADSCs have the potential to differentiate into VECs. 
Moreover the finding that the different flow patterns induce the different 
expression of the EC marker suggests the importance of specific flow 
pattern on the differentiation of ADSC-derived VECs. Further function of 
ADSC-derived VECs to communicate and regulate VICs will be 












Tissue engineering of pulmonary heart valves represents an enormous 
advantage for the treatment of Tetralogy of Fallot. It is important to find 
out the best decellularization method to preserve native structure of the 
leaflets before seeding with autologous cells.  
Porcine pulmonary heart valves were prepared and decellularized 
enzymatically. Six heart valves were treated with Trypsin/EDTA for 12 
hours (group 1) and six heart valves with AccutaseTM for 96 hours (group 
2). Heart valves were embedded in paraffin, analyzed histologically 
using H.E.-, Movat- pentachrome-, Elastica/van Gieson- and immuno-
histochemistry-staining using anti-collagen I and III. 
Movat-Pentachrome- and Elastica/van Gieson-staining demonstrated 
complete collagen structure in group 2 whereas in group 1 collagen 
structure was diffuse and not completely preserved. H.E.-staining 
showed remaining cell nuclei in group 1 revealing an incomplete 
decellularization. In contrast, group 2 revealed no cell nuclei. AccutaseTM 
incubation time was tested at different time points and demonstrated no 
cell nuclei and prevention of the structure after 96 hours whereas 
Trypsin/EDTA did not reveal complete structure after 12 hours. The 
collagen structure analyzed using anti-collagen I and III- staining 
indicated in group 1 destroyed cellular structure whereas in group 2 
various cell structures were completely preserved. 
In this study we demonstrated that AccutaseTM did not degrade the 
original structure of the leaflet while the original cells were completely 
removed. The rest of the DNA, we have found, will be analyzed by a 

























The isolation and cultivation of stem cells from experimental animals has 
become a common research technique in the field of regenerative 
medicine. The aim of this study was to establish the most appropriate 
anatomical location for harvesting of adipose tissue derived stem cells 
(ASCs) with perivascular localization (pericytes) in sheep. The first 
anatomical study was performed postmortem; fragments of subdermal 
adipose tissue collected from different locations were processed by 
standard histological methods. All subsequent interventions (n=19) were 
performed intra-vitally on sedated animals. Samples of about 0.5 cm3 
were harvested aseptically from the following anatomical locations: 
interscapular, paravertebral - lumbar and coccygeal, groin, perimammar, 
great omentum and perirenal. After harvesting, samples were placed in 
cell culture medium (DMEM/10% FBS10, 2% antibiotic/antifungal) and 
ASCs were isolated and cultured in vitro as described by Zuk (2001) and 
Gimble (2002) for subsequent use in studies of cardiovascular tissue 
regeneration. Microscopically we observed mature adipose tissue with 
the presence of small blood vessels in all tissues. Harvests from the 
paralombar areas did not yield ASCs. The vascular density was higher in 
the perivisceral and the somatic fat. However, due to the easier surgical 
approach, consistency of viable cells and to prevent postoperative 
complications, the interscapular area was chosen as the preferred site 
for isolation and culture of ASCs in adult sheep. Ongoing studies are 
testing the in vitro pluripotency of our sheep ASCs and their in vivo 

















Over 5,000 patients benefit from heart valve replacement in the UK 
annually. Cryopreserved allografts are the "gold standard" but these are 
subject to immunological responses leading to calcification and stenosis 
resulting in multiple reoperations. We have developed methods to 
remove the immunogenic cells from porcine aortic valves whilst 
preserving the biochemical and biomechanical properties (1, 2) and 
shown these to regenerate in the pulmonary position in sheep (3). This 
project aims to translate this technology to human cardiac valves for the 
benefit of patients in the UK. 
Five aortic and 3 pulmonary cryopreserved valves were treated 
sequentially with: hypotonic tris buffer, 0.1% (w/v) SDS in hypotonic 
buffer plus protease inhibitors and then treated with nucleases to 
remove nucleic acids. The histology and DNA content of four different 
regions of the acellular valves were compared to untreated 
cryopreserved valves. These studies were repeated on 4 pulmonary and 
4 aortic valves to determine the robustness of the process, and these 
valves were also tested for biocompatibility using extract and contact 
cytotoxicity assays, and analysed for collagen and glycosaminoglycan 
content. H&E staining of acellular tissues showed no evidence of cell 
nuclei or cell remnants. Quantitative analysis for total DNA content 
showed that acellular valves had less than 15ng DNA /mg wet tissue. 
There was no evidence of cytotoxicity and acellular tissue showed loss 
of GAGs and retention of collagen. 
Allogeneic cardiac valves successfully decellularised, whilst maintaining 
their histoarchitecture. The retention of collagen and loss of GAGs was 













Human mesenchymal stem cells (hMSCs) have shown to release a 
plethora of soluble factors that are associated with paracrine therapeutic 
effects. In vascular tissue engineering, seeded cells including hMSCs 
have shown to be a major factor involved in the induction of in situ 
remodeling and neo-tissue formation of bioengineered constructs. In 
addition, functional improvement following myocardial infarction has 
been reported after injection of MSC conditoned media (CM). 
Therefore the presented study aims at the in vitro comparison of 
different hMSC sources as to their chemoattractic properties. hMSCs 
were isolated from amniotic fluid, adipose tissue, bone marrow, 
wharton's jelly and vascular tissues as control cell source. For each 
source a phenotypic profile was achieved including expression of MSC 
markers, multilineage differentiation and proliferation capacities. CM of 
all cell sources were evaluated as to their chemoattractive potential to 
induce PBMC migration in a transwell migration assay. 
Transanastomotic ingrowth was examined with an in vitro endothelial 
scratch assay. 
The results pointed towards an increased monocyte migration in MSC 
CM with significantly higher values compared to controls. The 
comparative analysis showed that umbilical cord MSCs have the highest 
chemoattractive capacity. No significant differences between the cell 
sources were found in the endothelial scratch assay. 
In conclusion, these preliminary results suggest that CM of hMSCs has a 
major potential in the recruitment of monocytes in vitro, while the 
attraction of endothelial cells was not enhanced. Future experiments will 
aim at a profiling of the secretoma of all hMSC sources to identify 
















Cardiovascular tissue engineering aims at the creation of stem cell-
based living autologous substitutes to overcome the limitations of 
currently used cardiovascular replacement materials for cardiovascular 
valve disease. Experiments in sheep, being a gold standard animal 
model for in vivo preclinical cardiovascular assessment, cannot be used 
to unravel underlying mechanisms of tissue formation and in situ 
remodelling. Therefore the investigation of implanted tissue engineered 
vascular grafts (TEVGs) in the venous/arterial circulation of rodents has 
been intensively initiated as this would allow for the assessment of 
constructs remodelling in immune-incompetent or transgenic strains. 
Nevertheless to extrapolate findings from vessel-like structures to more 
complex "dynamic" structures of valves, more hemodynamically relevant 
model must be created, which was the aim of this study. For this stented 
monoleaflet PGA-P4HB valves (n=5, length= 2mm, diameter=1.5mm) 
were created and successfully implanted infrarenaly into abdominal 
aorta of Wistar Outbreed Rats (n=5) by catheter based technique. All 
animals survived the entire time of experiment and were stable during 
the surgery and post-operative ultrasound evaluation. Also no significant 
hemodynamic changes were observed. Nevertheless ultrasonographic 
evaluation revealed only minor leaflet movement (n=2 out of 5) in arterial 
circulation, most probably due to geometrical and hemodynamic 
reasons. Histological evaluation revealed some infiltration (within 3 
hours) both into the wall and the leaflet and no signs for thrombus 
formation. These findings support the need for valve like structures 
assessment in the environment more similar to orthotopic cardiac one 
with more physiological flow conditions as well as structural adaptations 













The worldwide prevalence of degenerative mitral valve pathologies 
coupled with reparative and replacement strategies would beneficiate 
from improved solutions offered by tissue engineering strategies 
employing biological scaffolds and stem cells. In order to develop mitral 
valve scaffolds with optimal mechanical and biological properties, 
porcine fresh mitral valves were subjected to the removal of all cellular 
components, while leaving the extracellular matrix components intact. 
These acellular scaffolds were treated with penta-galloyl glucose (PGG), 
a polyphenol that binds to collagen and elastin and renders the 
extracellular matrix of the annulus, leaflets, and chordae tendinae 
resistant to rapid enzymatic degradation. Scaffolds were also evaluated 
for their mechanical properties, using biaxial tensile tests and thermal 
denaturation profiles. After seeding the annulus scaffolds with human 
smooth muscle cells and the leaflets with human adipose tissue derived 
stem cells, the constructs were mounted in a heart valve bioreactor. Cell 
proliferation and viability were evaluated after testing under static and 
dynamic bioreactor conditions for three weeks. Histological and 
immunohistochemical results indicated that there was complete removal 
of cellular components including DNA and cell proteins, yet a clear 
retention of both collagen and elastin. PGG treatment stabilized the 
extracellular matrix components of the scaffolds, improving the 
resistance to proteases and the mechanical properties of the leaflets and 
annulus. Cells were successfully injected within the scaffold and were 
maintained alive in vitro. Overall, we have developed a cytocompatible 

















The long-term goal of this project is to generate living, tissue-engineered 
(TE) heart valves from biological scaffolds and autologous stem cells. At 
the basic level, a successful TE device must withstand mechanical 
stresses immediately upon implantation without posing risks of 
immunological rejection. The three main challenges to this objective are 
complete decellularization of porcine aortic valve roots (AVR) including 
the aortic root wall and sinus, efficacious seeding of adult stem cells 
within cusps, and the controlled dynamic progressive conditioning before 
implantation. We hypothesized that these challenges will not likely be 
overcome without using advanced bioreactor systems. We developed 
integrated platform technologies for complete AVR decellularization and 
cell seeding. Porcine AVRs were mounted into universal “no-touch” 
tissue-holding devices, treated with detergents and enzymes in a 
pulsatile perfusion system, and analyzed by histology and DNA 
quantitation. Human adipose-tissue derived stem cells (hASCs) were 
injected into cusps prior to surface recellularization in seeding chambers. 
The AVRs were progressively conditioned in heart valve bioreactors until 
reaching pulmonary conditions. Cell retention was assessed through 
surface imaging and histology. Decellularization of the entire porcine 
AVR (especially the aortic wall) was not possible through immersion 
techniques, but was successful using our pulsatile perfusion system. 
Utilizing the rotating seeding chambers resulted in more complete 
seeding as compared to dropwise seeding methods. Progressive 
conditioning regimens facilitated good initial cellular retention and stem 
cell pre-differentiation into cells resembling valvular interstitial cells. 
Overall, we have developed the basic equipment and expertise 





















An increasing number of young patients are choosing bioprostheses for 
aortic valve replacement, but Ross operation deserves consideration as 
an alternative biological substitute. Reoperation rates after the Ross 
procedure and after bioprosthetic AVR, however remain a concern in 
these patients. 
We report reasons of reoperation after the Ross procedure for different 
age groups. 
Reoperation rates of 1.925 patients (mean age 41.2±15.3 years, 1.444 
male) with a mean follow-up of 7.4±4.7 years (range 0.00 - 18.51 years, 
12866.6 patient years) were analyzed in three age groups (Group I < 40 
years, Group II 40-60 years, Group III > 60 years). Reasons of 
reoperation were figured out. 
In Group I 12% (after 4.6±4.2 years), in Group II 6% (after 5.12±4.65 
years) and in Group III 9% after (5.0±4.8 years) of the patients had to be 
reoperated. Mean interval to reoperation in bioprostheses was about 8 
years in younger and about 13 years in middle aged patients. Mots 
frequent reasons of reoperation were in: Group I SVD of the homograft 
(7%), Group II NSVD of the autograft (3%) and Group III SVD of the 
autograft (6.5%). 
There is some evidence that in younger patients the reason of 
reoperation after Ross procedure is mainly SVD of the homograft and if 
there is a need for reoperation it is probably earlier than in patients with 
bioprostheses. 
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